Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
By combining ULK1 and ULK2 inhibitors with MAPKAP pathway inhibitors, the selection and toxicity of existing autophagy inhibitors were solved, effective inhibition of autophagy in mutant Ras cancer and Parkinson's disease was achieved, and tumor growth and neurodegeneration were reduced. Complex survival mechanisms of sexual diseases.
Patent Information
- Application Number
- CN202410819165.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-07
- Filing Date
- 2020-05-08
- Publication Date
- 2024-11-12
AI Technical Summary
Existing autophagy inhibitors such as chloroquine and hydroxychloroquine have multiple mechanisms of action, resulting in toxic side effects, and insufficient selectivity, making it difficult to effectively block the autophagy process, especially in mutant Ras cancer and Parkinson's disease. The existing targets are The treatment has limited efficacy.
Develop inhibitors of ULK1 and ULK2 activity as new autophagy inhibitors block ULK kinase activity through specific compound structures, combining MAPKAP pathway inhibitors or other targeted therapeutic agents for the treatment of cancer and neurodegenerative diseases .
Effectively inhibit the autophagy process, reduce tumor growth and cancer cell survival, reduce the complex survival mechanism of mutant Ras cancer, and at the same time reduce the excessive activation of autophagy in Parkinson's disease, providing a safer and more selective treatment plan.
Smart Images

Figure CN118930524A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 202080049700.3, application date May 8, 2020, and invention name “Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to USSN 62 / 846,251 filed on May 10, 2019, USSN 62 / 846,258 filed on May 10, 2019, USSN 62 / 911,728 filed on October 7, 2019, and USSN 62 / 911,730 filed on October 7, 2019, the contents of each of which are incorporated herein by reference in their entirety.
[0004] Sequence Listing
[0005] This application contains a sequence listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy, created on May 5, 2020, is named DCP-079WO_SL.txt and is 27,196 bytes in size. Background Art
[0006] Autophagy (literally "self-eating") is a process that enables cells to recycle organelles, proteins, stored lipids, glucagon and other substances for the purpose of generating nutrition under stress. These cell contents are recycled by being engulfed in a vesicle called an autophagosome. Subsequently, the autophagosome merges with the degraded autophagosome contents to recycle nutrients to the lysosomes of the cell. Tumor cells are prone to activated autophagy because these cells have high metabolic demands, experience cell stress, and are usually in an oxygen-deficient environment with limited blood flow and nutrient supply. In addition, chemotherapy and targeted therapy have been shown to induce autophagy as a mechanism of treatment resistance, and it has been shown that autophagy inhibition (by gene function loss mutations in autophagy genes or by pharmacological means) and a combination of chemotherapeutic regimens inhibit tumor growth and trigger tumor cell apoptosis to a higher degree than single-agent chemotherapy.
[0007] Mutant Ras proteins drive approximately 30% of all human cancers - including 95% of pancreatic cancers and 45% of colorectal cancers, and treatment of these mutant Ras cancers is currently an area of high unmet medical need. Mutant Ras cancers are highly proliferative and depend on basal levels of autophagy for survival, suggesting that autophagy inhibition is a viable treatment approach in these "autophagy addicted" cancers.
[0008] At present, the most widely used autophagy inhibitors are chloroquine and hydroxychloroquine, which are known antimalarials. It is believed that these antimalarials block autophagy by being isolated in the lysosomal compartment, increasing the pH of these lysosomes and thereby inactivating the proteases that degrade and recycle nutrients. These antimalarials have multiple mechanisms of action in addition to inhibiting lysosomes and are known to induce retinopathy in patients. Therefore, there is a need for more selectively blocking autophagy and targeting agents that do not exhibit the toxicity of these antimalarials. ULK1 kinase is an autophagy initiation protein and a serine / threonine kinase. The ULK1 kinase complex is activated in response to cell stress including nutrient deficiency and energy consumption. Nutritional deficiency activates ULK kinase activity via inhibition of mTORC1, and energy consumption activates ULK kinase activity via activation by AMP-activated protein kinase AMPK. Importantly, the kinase-inactive mutants of ULK kinase block the initiation of typical autophagy, indicating that small molecule inhibitors of ULK kinase activity should be able to block autophagy.
[0009] Additional mechanistic studies have shown that ULK1 gene deletion inhibits autophagy in cancer cells, abolishing FOX3A conversion and upregulation of the pro-apoptotic protein PUMA. In addition to the classical activation of canonical autophagy, ULK1 kinase activity has also been shown to be required for Bcl-2-L-13-mediated mitochondrial autophagy (autophagy of damaged mitochondria). ULK1 and ULK2 kinases have also been shown to rewire cancer cell glucose metabolism. ULK inhibitors can also be used to block these atypical tumor-promoting ULK activities.
[0010] Autophagy is also upregulated in cancer host cells and tissues. Autophagy in pancreatic tissue stellate cells has been shown to support tumor growth. Pancreatic stellate cells have been shown to support pancreatic cancer tumor metabolism via autophagic alanine secretion. It has been shown that inhibition of host tissue autophagy causes consumption of circulating arginine (an amino acid required for tumor metabolism and growth) via increased liver-mediated arginase secretion. It has also been shown that ULK1 kinase activation inactivates the STING pathway in immune cells via inhibitory phosphorylation of STING, regulating negative feedback mechanisms to limit interferon-mediated innate immune cell responses. Therefore, autophagy is activated not only in tumor cells (cancer cells spontaneously), but also in other cells in the tumor microenvironment or host tissue (cancer cells non-spontaneously) to support tumor survival and growth.
[0011] Mutated Ras cancers are addicted to autophagy. In pancreatic cancer, mutant Ras signals primarily through the MAPKAP pathway. Mutated Ras activates RAF kinase, which in turn activates MEK kinase, and finally activates ERK kinase: mutant Ras→RAF→MEK→ERK. Although mutant Ras signaling passes through the MAPKAP pathway, inhibitors of this pathway provide no or minimal clinical benefit when used as a single agent in clinical trials. It has recently been reported that MAPKAP pathway inhibition induces autophagy as a compensatory survival mechanism. When MEK inhibitors are combined with the autophagy inhibitor hydroxychloroquine, there is synergistic activity that causes regression of multiple mutant Ras cancers or mutant BRAF cancers. Similarly, when ERK inhibitors are combined with the autophagy inhibitors hydroxychloroquine or chloroquine, there is synergistic activity that causes inhibition of mutant Ras pancreatic cancer. It has been demonstrated that genetic depletion of RAF kinases (CRAF and BRAF) causes synergistic anti-tumor activity in mutant Ras cancer cell lines when autophagy is also genetically depleted. Recent publications highlight that dual inhibition of the MAPKAP pathway and the autophagy pathway in complex in mutant Ras cancers is a promising treatment approach for patients with mutant Ras cancers. Other targeted therapies and chemotherapeutics have also been shown to activate tumor autophagy as a resistance mechanism; thus there is a rationale for combining such targeted therapeutics or chemotherapeutics with autophagy inhibitors.
[0012] Mutations in the gene encoding the LRRK2 kinase cause Parkinson's disease. LRRK2 point mutations are found in both familial (hereditary) Parkinson's patients and sporadic Parkinson's patients. The most common LRRK2 mutation in Parkinson's disease is LRRK2 G2019S. These LRRK2 mutations are gain-of-function mutations that lead to overactivation of LRRK2 signaling. Continuous autophagy is a process used by brain neuronal cells to maintain health and homeostasis. Autophagy is a process that allows cells to recognize, locate and destroy aged organelles and structural elements within cells, and specifically, in the case of proteins known to aggregate in neurons, autophagy eliminates such toxic protein aggregates to maintain neuronal health. LRRK2 activity inhibits autophagy, and the LRRK2 G2019S gain-of-function mutation is even more inhibitory and has been associated with aggressive forms of Parkinson's disease.
[0013] Increased LRRK2 kinase activity is also associated with immunoinflammatory diseases including colitis and Crohn's disease, as well as inflammatory bowel disease. In the gastrointestinal tract, LRRK2 is present in antigen presenting cells including dendritic cells. LRRK2 activity has been shown to be critical in pattern recognition receptor-1-mediated innate immune responses, including NFkB pathway activation and increased TNF-α production in dendritic cells of Crohn's disease patients.
[0014] LRRK2 inhibitors are sought for the treatment of neurodegenerative diseases including Parkinson's disease, and are also sought for the treatment of gastrointestinal diseases including Crohn's disease, ulcerative colitis, and inflammatory bowel disease.
[0015] There is a need for new targeted therapies that inhibit autophagy and can be used in combination with MAPKAP pathway inhibitors, chemotherapeutic agents, and / or other targeted therapeutics. Summary of the invention
[0016] Described herein are compounds, pharmaceutical compositions and their use as medicaments in the treatment of conditions such as cancer, methods for their preparation, and pharmaceutical compositions containing them as active ingredients that are autophagy inhibitors. Such pharmaceutical compositions may include the compounds as single active agents or in combination with other active agents in the presence of pharmaceutically acceptable excipients. In one embodiment, the compounds described are inhibitors of ULK kinase activity, including ULK1 and ULK2 activity.
[0017] For example, the compounds provided herein can be described as represented by formula (I)
[0018]
[0019] or a pharmaceutically acceptable salt, enantiomer, stereoisomer or tautomer thereof, wherein: W is CH or N; X is CH or N; Y is C(R 3 ) or N; R 1 is selected from the group consisting of halogen, cyano, C1-C5 alkyl and C3-C5 cycloalkyl, wherein each C1-C5 alkyl and C3-C5 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine; R 2 R is selected from the group consisting of H, halogen, cyano, C1-C5 alkyl, C3-C6 cycloalkyl, C2-C5 alkenyl, C2-C5 alkynyl, C1-C5 alkoxy and C1-C5 alkoxy-C2-C5 alkyl, wherein each of C1-C5 alkyl, C3-C6 cycloalkyl, C2-C5 alkenyl, C2-C5 alkynyl and C1-C5 alkoxy may be optionally substituted by one, two or three independent occurrences of fluorine or cyano; 3 and R 33 is independently selected at each occurrence from the group consisting of: H, halogen, C 1- C6 alkyl and C 1- C6 alkoxy, wherein each C1-C6 alkyl and C1-C6 alkoxy may be optionally substituted with one or more independent occurrences of fluorine; R 4 Selected from the following group: B, D, NR 6 R 9 NR 6 -(C(R 10 )2)p -NR 9 R 9 、C(O)-NR 6 R 9 ; C(O)-B; C(O)-D and CN; B is selected from N-linked heterocyclic groups and heteroaryls having at least one nitrogen and optionally having additional ring nitrogen or oxygen, wherein B may be optionally formed on one or more available carbons by R 7 substituted and optionally substituted on an available nitrogen by R 9 D is selected from C-linked heterocyclic and heteroaryl groups having at least one nitrogen and optionally additional ring nitrogen or oxygen, wherein D may be optionally substituted on one or more available carbons by R 7 substituted and optionally substituted on an available nitrogen by R 9 Replacement; R 5 R is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and heterocyclyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; 7 is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, cyano, and (C(R 10 )2) h -NR 9 R 9 , wherein each C1-C6 alkyl group and C3-C6 cycloalkyl group may be optionally substituted by one or more independently occurring fluorine groups, or two R 7 Combined with the atom to which it is attached to form an oxo group; R 6 and R 9 Each occurrence is independently selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, C 1- C5 alkoxy-C2-C5 alkyl, C(=O)R 5 、SO2R 5 and D, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; R 10 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl, wherein each C1-C3 alkyl and C3-C5 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 10 The carbon atoms to which they are attached are joined together to form a C3-C5 cycloalkyl group; Z is selected from the group consisting of a 4-membered lactam ring bonded via a nitrogen atom or a 6-10-membered lactam ring bonded via a nitrogen atom, wherein when the lactam ring is a 6-10-membered ring, the lactam ring atom may optionally be oxygen or NR 6 , and the available carbon atoms on the 4-membered lactam ring or the 6-10-membered lactam are optionally connected via R 36 Replacement; R36 R is independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 36 joined together with the carbon to which they are attached to form a C3-C6 cycloalkyl; h is 1, 2 or 3; m is 0, 1, 2 or 3; n is 2, 3 or 4; and p is 2 or 3; provided that X and Y are not both N. SUMMARY OF THE INVENTION
[0021] The features and other details of the present disclosure will now be described more clearly. Specific terms used in this specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of this disclosure and as understood by those skilled in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art.
[0022] definition
[0023] As used herein, the term "alkyl" refers to a saturated straight or branched hydrocarbon. Exemplary alkyls include, but are not limited to, straight or branched hydrocarbons having 1-6, 1-5, 1-4, 1-3 or 1-2 carbon atoms, respectively referred to herein as C1-C6 alkyl, C1-C5 alkyl, C1-C4 alkyl, C1-C3 alkyl and C1-C2 alkyl. Exemplary alkyls include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-butyl, 3-methyl-2-butyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, etc.
[0024] As used herein, the term "alkenyl" refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond. Exemplary alkenyl groups include, but are not limited to, straight or branched groups having 2-6 or 3-4 carbon atoms, referred to herein as C2-C6 alkenyl and C3-C4 alkenyl, respectively. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, and the like.
[0025] As used herein, the term "alkoxy" refers to a straight or branched chain alkyl group (alkyl-O-) attached to an oxygen. Exemplary alkoxy groups include, but are not limited to, alkoxy groups having 1-6 or 2-6 carbon atoms, referred to herein as C1-C6 alkoxy and C2-C6 alkoxy, respectively. Exemplary alkoxy groups include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like.
[0026] As used herein, the term "alkoxyalkyl" refers to a straight or branched chain alkyl group connected to an oxygen, connected to a second straight or branched chain alkyl group (alkyl-O-alkyl-). Exemplary alkoxyalkyl groups include, but are not limited to, alkoxyalkyl groups referred to herein as C1-C6 alkoxy-C1-C6 alkyl groups, each of which independently contains 1-6 carbon atoms. Exemplary alkoxyalkyl groups include, but are not limited to, methoxymethyl, 2-methoxyethyl, 1-methoxyethyl, 2-methoxypropyl, ethoxymethyl, 2-isopropoxyethyl, and the like.
[0027] As used herein, the term "alkynyl" refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond. Exemplary alkynyl groups include, but are not limited to, straight or branched groups having 2-6 or 3-6 carbon atoms, referred to herein as C2-C6 alkynyl and C3-C6 alkynyl, respectively. Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, and the like.
[0028] The term "cyano" as used herein refers to the group -CN.
[0029] As used herein, the term "cycloalkyl" or "carbocyclyl" refers to a saturated or partially unsaturated hydrocarbon group having, for example, 3-6 or 4-6 carbons, referred to herein as C3-C6 cycloalkyl or C4-C6 cycloalkyl, respectively. Exemplary cycloalkyls include, but are not limited to, cyclohexyl, cyclopentyl, cyclopentenyl, cyclobutyl or cyclopropyl.
[0030] As used herein, the term "cycloalkoxy" refers to a cycloalkyl group (cycloalkyl-O-) connected to an oxygen. Exemplary cycloalkoxy groups include, but are not limited to, cycloalkoxy groups with 3-6 carbon atoms, referred to herein as C3-C6 cycloalkoxy groups. Exemplary cycloalkoxy groups include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, etc.
[0031] As used herein, the term "halo" or "halogen" refers to F, Cl, Br or I.
[0032] As used herein, the term "heteroaryl" refers to a monocyclic aromatic 5 or 6-membered ring system containing one or more heteroatoms such as nitrogen, oxygen and sulfur, for example one to three heteroatoms. Where possible, the heteroaryl ring may be connected to an adjacent group via carbon or nitrogen. Examples of heteroaryl rings include, but are not limited to, furan, thiophene, pyrrole, thiazole, oxazole, isothiazole, isoxazole, imidazole, pyrazole, triazole, pyridine or pyrimidine, etc.
[0033] The term "heterocyclyl" or "heterocyclic group" is well-known in the art and refers to a saturated or partially unsaturated 4-10 ring structure, including a monocyclic, bridged or fused ring, and such a ring structure includes one to three heteroatoms such as nitrogen, oxygen and sulfur. Where possible, the heterocyclyl ring may be connected to an adjacent group via carbon or nitrogen. Examples of heterocyclyl include, but are not limited to, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, oxetane, azetidine, tetrahydrofuran or dihydrofuran, etc.
[0034] As used herein, the term "lactam" refers to a cyclic amide of an aminocarboxylic acid having a 1-azacycloalkane-2-one structure or an analog having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. "α-lactam" refers to a lactam consisting of a 3-membered ring. "β-lactam" refers to a lactam consisting of a 4-membered ring. "γ-lactam" refers to a lactam consisting of a 5-membered ring. "δ-lactam" refers to a lactam consisting of a 6-membered ring. "ε-lactam" refers to a lactam consisting of a 7-membered ring.
[0035] The term "oxo" as used herein refers to the group =0.
[0036] "Combination therapy" is a treatment that involves administering to a patient in need thereof two or more therapeutic agents, eg, a compound of Formula I and a MAPKAP pathway inhibitor.
[0037] "Disease," "disorder," and "condition" are used interchangeably herein.
[0038] "Individual", "patient" or "subject" are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses or primates, and most preferably humans. The compounds described herein can be administered not only to mammals such as humans, but also to other mammals, such as animals requiring veterinary treatment, such as domestic animals (e.g., dogs, cats, etc.), farm animals (e.g., cows, sheep, pigs, horses, etc.), and laboratory animals (e.g., rats, mice, guinea pigs, etc.).
[0039] "MAPKAP pathway inhibitors" are inhibitors of the MAP kinase signaling pathway. This pathway inhibitor includes Ras inhibitors (e.g., AMG-510, MRTX 849), RAF inhibitors (e.g., dabrafenib, vemurafenib, LY3009120), MEK inhibitors (e.g., trametinib, binimetinib, selumetinib, cobimetinib) and ERK inhibitors (e.g., ulixertinib, SCH772984, LY3214996). The terms "MAPKAP pathway inhibitors" and "MAPKAP kinase inhibitors" are used interchangeably herein.
[0040] "Pharmaceutically or pharmacologically acceptable" includes molecular entities and compositions that do not produce adverse, allergic or other untoward reactions when administered to animals or humans, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by the FDA Office of Biologics standards.
[0041] As used herein, the term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" refers to any and all solvents, dispersion media, coatings, isotonic agents, absorption delaying agents, etc. that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The composition may also contain other active compounds that provide supplementary, additional or enhanced therapeutic functions.
[0042] As used herein, the term "pharmaceutical composition" refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
[0043] As used herein, the term "pharmaceutically acceptable salt" refers to a salt having an acidic or basic group that may be present in the compound used in the composition. The compounds included in the composition of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. Acids that can be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are acids that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotine, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentianin, fumarate, gluconate, glucuronate, sucrose, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)). The compounds included in the compositions of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal salts or alkaline earth metal salts, particularly calcium salts, magnesium salts, sodium salts, lithium salts, zinc salts, potassium salts and iron salts. The compounds included in the compositions of the present invention that include basic or acidic moieties may also form pharmaceutically acceptable salts with various amino acids. The compounds of the present disclosure may contain both acidic and basic groups; for example, an amino group and a carboxylic acid group. In such cases, the compounds may exist as acid addition salts, zwitterions or basic salts.
[0044] The compounds of the present disclosure may contain one or more chiral centers and therefore exist as stereoisomers. The term "stereoisomer" when used herein consists of all enantiomers or diastereomers. Depending on the configuration of substituents around the stereogenic carbon atom, these compounds may be designated by the symbols "(+)", "(-)", "R" or "S", but those skilled in the art will recognize that the structure may implicitly represent the chiral center. The compounds described in the present invention encompass various stereoisomers of these compounds and mixtures thereof. In nomenclature, mixtures of enantiomers or diastereomers may be designated as "(±)", but those skilled in the art will recognize that the structure may implicitly represent the chiral center.
[0045] In this specification, the term "therapeutically effective amount" means the amount of the compound of the present invention that elicits the biological or medical response of a tissue, system or animal (e.g., mammal or human) that a researcher, veterinarian, medical doctor or other clinician is seeking. The compounds described herein are administered in a therapeutically effective amount to treat a condition.
[0046] "Treatment" includes any action that results in improvement of a condition, disease, disorder, etc., such as alleviation, reduction, regulation, or elimination.
[0047] The present disclosure also encompasses isotopically labeled compounds identical to the compounds described herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include, respectively, 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine of Cl. For example, the compounds of the present disclosure may have one or more H atoms replaced with deuterium.
[0048] Individual enantiomers and diastereomers of the compounds of the invention may be prepared synthetically from commercially available starting materials containing asymmetric or stereogenic centers, or by preparing racemic mixtures followed by resolution methods known to those of ordinary skill in the art. These resolution methods are exemplified by (1) coupling a mixture of enantiomers to a chiral auxiliary, separating the resulting mixture of diastereomers by recrystallization or chromatography and releasing the optically pure product from the auxiliary, (2) forming salts using an optically active resolution agent, (3) directly separating a mixture of optical enantiomers on a chiral liquid chromatography column, or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures may also be resolved into their component enantiomers by known methods such as chiral phase liquid chromatography or crystallization of compounds in chiral solvents. Stereoselective syntheses, which are chemical or enzymatic reactions in which a single reactant forms an unequal mixture of stereoisomers during the generation of a new stereocenter or during the conversion of a pre-existing stereocenter, are known in the art. Stereoselective syntheses encompass both enantio- and diastereo-stereoselective transformations and may involve the use of chiral auxiliary agents. See, e.g., Carreira and Kvaerno, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.
[0049] Compound
[0050] Described herein are compounds represented by Formula I:
[0051]
[0052] or a pharmaceutically acceptable salt, enantiomer, stereoisomer or tautomer thereof, wherein: W is CH or N; X is CH or N; Y is C(R 3 ) or N; R 1 is selected from the group consisting of halogen, cyano, C1-C5 alkyl and C3-C5 cycloalkyl, wherein each C1-C5 alkyl and C3-C5 cycloalkyl may be optionally substituted by one, two or three independent occurrences of fluorine; R 2 R is selected from the group consisting of H, halogen, cyano, C1-C5 alkyl, C3-C6 cycloalkyl, C2-C5 alkenyl, C2-C5 alkynyl, C1-C5 alkoxy and C1-C5 alkoxy-C2-C5 alkyl, wherein each of C1-C5 alkyl, C3-C6 cycloalkyl, C2-C5 alkenyl, C2-C5 alkynyl and C1-C5 alkoxy may be optionally substituted by one, two or three independent occurrences of fluorine or cyano; 3 and R 33 is independently selected at each occurrence from the group consisting of: H, halogen, C 1- C6 alkyl and C 1- C6 alkoxy, wherein each C1-C6 alkyl and C1-C6 alkoxy may be optionally substituted with one or more independent occurrences of fluorine; R 4 Selected from the following group: B, D, NR 6 R 9 NR 6 -(C(R 10 )2) p -NR 9 R 9 、C(O)-NR 6 R 9 ; C(O)-B; C(O)-D and CN; B is selected from N-linked heterocyclic groups and heteroaryls having at least one nitrogen and optionally having additional ring nitrogen or oxygen, wherein B may be optionally formed on one or more available carbons by R 7 substituted and optionally substituted on an available nitrogen by R 9 D is selected from C-linked heterocyclic and heteroaryl groups having at least one nitrogen and optionally additional ring nitrogen or oxygen, wherein D may be optionally substituted on one or more available carbons by R 7 substituted and optionally substituted on an available nitrogen by R 9 Replacement; R 5 R is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and heterocyclyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; 7 is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, cyano, and (C(R 10 )2)h-NR9 R 9 , wherein each C1-C6 alkyl group and C3-C6 cycloalkyl group may be optionally substituted by one or more independently occurring fluorine groups, or two R 7 Combined with the atom to which it is attached to form an oxo group; R 6 and R 9 Each occurrence is independently selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, C 1- C5 alkoxy-C2-C5 alkyl, C(=O)R 5 、SO2R 5 and D, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; R 10 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl, wherein each C1-C3 alkyl and C3-C5 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 10 The carbon atoms to which they are attached are joined together to form a C3-C5 cycloalkyl group; Z is selected from the group consisting of a 4-membered lactam ring bonded via a nitrogen atom or a 6-10-membered lactam ring bonded via a nitrogen atom, wherein when the lactam ring is a 6-10-membered ring, the lactam ring atom may optionally be oxygen or NR 6 , and the available carbon atoms on the 4-membered lactam ring or the 6-10-membered lactam are optionally connected via R 36 Replacement; R 36 R is independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 36 joined together with the carbon to which they are attached to form a C3-C6 cycloalkyl; h is 1, 2 or 3; m is 0, 1, 2 or 3; n is 2, 3 or 4; and p is 2 or 3; provided that X and Y are not both N.
[0053] In some embodiments, W is N. In some embodiments, X is CH and Y is N. In some embodiments, X is CH and Y is C(R 3 ).
[0054] In some embodiments, Z is selected from:
[0055] and Wherein, V is selected from the following group: oxygen, CH2 and NR 6 ; R 34 independently selected at each occurrence from H and R 36 , where R 36are independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, or two R 36 joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl; q is 0, 1, 2 or 3; and r is 2 or 4, provided that if q is 0, then r is not 2.
[0056] In some embodiments, Z is selected from:
[0057] and Wherein, V is selected from the following group: oxygen, C(R 34 )2 and NR 6 ; R 34 independently selected at each occurrence from H and R 36 , where R 36 are independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, or two R 36 joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl group; q is 0, 1, 2 or 3; and r is 2 or 3, provided that if q is 0, then r is not 2.
[0058] In some embodiments, Z is selected from the group consisting of:
[0059]
[0060] and
[0061] In some embodiments, Z is selected from:
[0062] and Wherein, V is selected from the following group: oxygen, CH2 and NR 6 ; q is 0, 1, 2 or 3; and r is 2 or 3, provided that if q is 0, then r is not 2.
[0063] In some embodiments, Z is selected from the group consisting of:
[0064]
[0065] and
[0066] In some embodiments, R 4 For B.
[0067] In some embodiments, R 4 Select from the following group:
[0068]
[0069] and Where u is 1 or 2.
[0070] In some embodiments, R 4 Select from the following group:
[0071]
[0072] and
[0073] In some embodiments, R 4 Select from the following group:
[0074] and
[0075] In some embodiments, R 4 Select from the following group:
[0076]
[0077] and
[0078] In some embodiments, R 4 is D.
[0079] In some embodiments, R 4 Select from the following group:
[0080]
[0081] and
[0082] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.
[0083] In some embodiments, R 1 Selected from the group consisting of halogen, C 1- C5 alkyl and C 3- C5 cycloalkyl, wherein C 1- C5 alkyl may be optionally substituted with one, two or three occurrences of fluorine. 1 is CF3. In some embodiments, R 1 is CF2H. In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 It is cyclopropyl.
[0084] In some embodiments, R 2 is selected from the group consisting of H, C3-C5 cycloalkyl, C1-C5 alkyl, halogen, CN, C2-C5 alkenyl, and C2-C5 alkynyl, wherein the C1-C5 alkyl may be optionally substituted with one, two, or three independent occurrences of fluorine. 2 Select from the following group: C 1-2 Alkyl and C 3-4 In some embodiments, R 2 Selected from the group consisting of chlorine and bromine.
[0085] In some embodiments, R 2 Select from the following group: C 1- C5 alkyl, H and C3-C4 cycloalkyl. In some embodiments, R 2 is selected from the group consisting of C1-C2 alkyl and C3-C4 cycloalkyl. 2 Selected from the group consisting of chlorine and bromine.
[0086] In some embodiments, n is 3.
[0087] In some embodiments, the compound is represented by Formula II:
[0088]
[0089] or a pharmaceutically acceptable salt thereof, wherein: n is 2, 3 or 4; R 1 is selected from the group consisting of halogen, cyano, C1-C5 alkyl and C3-C5 cycloalkyl, wherein each C1-C5 alkyl and C3-C5 cycloalkyl may be optionally substituted with one, two or three independent occurrences of fluorine; R 2 is selected from the group consisting of halogen, C1-C2 alkyl and C3-C4 cycloalkyl; R 4 Select from the following group:
[0090] and R 6 and R 9 is independently selected at each occurrence from the group consisting of: H, C1-C6 alkyl, C3-C6 cycloalkyl, C(=O)R 5 、SO2R 5 and D, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; R 5 R is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and heterocyclyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; 7R is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl and C3-C6 cycloalkyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 7 and the atoms to which they are attached are joined together to form an oxo group; D is selected from a C-linked heterocyclic group and a heteroaryl group having at least one nitrogen and optionally having additional ring nitrogen or oxygen, wherein D may be optionally replaced by R on one or more available carbons 7 substituted and optionally substituted on an available nitrogen by R 9 Substitution; Z is selected from the following group:
[0091]
[0092] and And R 34 independently selected at each occurrence from H and R 36 , where R 36 is independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, wherein each C1-C5 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 36 Joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl group.
[0093] In some embodiments, R 1 Selected from the group consisting of halogen, C 1- C5 alkyl and C 3- C5 cycloalkyl, wherein C 1- The C5 alkyl group may optionally be substituted with one, two or three occurrences of fluorine and C 3- C5 cycloalkyl substituted. In some embodiments, R 1 is CF3. In some embodiments, R 1 is CF2H. In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 It is cyclopropyl.
[0094] In some embodiments, R 2 is selected from the group consisting of H, C3-C4 cycloalkyl, C1-C5 alkyl and halogen. 2 Selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine.
[0095] In some embodiments, R 4 Select from the following group:
[0096]
[0097] and
[0098] In some embodiments, R 4 Select from the following group:
[0099] and
[0100] In some embodiments, each R 6 and R 9 Independently selected from the group consisting of H, C1-C6 alkyl and C3-C6 cycloalkyl, wherein each of C1-C6 alkyl and C3-C6 cycloalkyl is optionally substituted with one or more independent occurrences of fluorine.
[0101] In some embodiments, R 7 For H.
[0102] In some embodiments, R 34 is independently selected at each occurrence from the group consisting of H and C1-C5 alkyl, wherein the C1-C5 alkyl may be optionally substituted with one, two, or three independent occurrences of fluorine. 34 Joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl group.
[0103] In some embodiments, Z is selected from the group consisting of:
[0104]
[0105] and
[0106]
[0107] In some embodiments, Z is selected from the group consisting of:
[0108]
[0109] and
[0110] In some embodiments, n is 3.
[0111] In one embodiment, the compound is represented by a formula selected from the group consisting of:
[0112]
[0113] and Among them, R 1R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 9 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl; 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0114] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0115] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 R is independently selected at each occurrence from H and C1-C3 alkyl; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is independently selected at each occurrence from H and C1-C3 alkyl; each R 34 is H; and n is 3.
[0116] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0117] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0118] and Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl, and C3-C5 cycloalkyl; and n is 3.
[0119] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R at each occurrence is selected from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is selected from H and C1-C3 alkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3.
[0120] In one embodiment, the compound is represented by a formula selected from the group consisting of:
[0121]
[0122] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 9 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl; 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0123] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0124] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 R is independently selected at each occurrence from H and C1-C3 alkyl; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is independently selected at each occurrence from H and C1-C3 alkyl; each R 34 is H; and n is 3.
[0125] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0126] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0127] and Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl, and C3-C5 cycloalkyl; and n is 3.
[0128] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R at each occurrence is selected from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is selected from H and C1-C3 alkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from the group consisting of C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from the group consisting of C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3.
[0129] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0130]
[0131] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0132] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0133] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0134] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34is H; and n is 3.
[0135] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0136] and Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3.
[0137] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is selected from C1-C3 alkyl and C3-C4 cycloalkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3.
[0138] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0139]
[0140] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 9 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl; 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0141] In some embodiments, R1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0142] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 R is independently selected at each occurrence from H and C1-C3 alkyl; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is independently selected at each occurrence from H and C1-C3 alkyl; each R 34 is H; and n is 3.
[0143] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0144] In some embodiments, the compound is represented by a formula selected from:
[0145] and Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl, and C3-C5 cycloalkyl; and n is 3.
[0146] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R at each occurrence is selected from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is selected from H and C1-C3 alkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3.
[0147] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0148]
[0149] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0150] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0151] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0152] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0153] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0154]
[0155] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3.
[0156] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is selected from C1-C3 alkyl and C3-C4 cycloalkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3.
[0157] In some embodiments, the compound is represented by:
[0158]
[0159] Among them, R 1 is selected from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; and R 9 is selected from the group consisting of C1-C3 alkyl, H, and C3-C5 cycloalkyl. 1 CF3; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 is bromine; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 CF2H; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H.
[0160] In some embodiments, the compound is represented by:
[0161]
[0162] Among them, R 1 is selected from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; and R 9 is selected from the group consisting of C1-C3 alkyl, H, and C3-C5 cycloalkyl. 1 CF3; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 is bromine; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 CF2H; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H.
[0163] In some embodiments, the compound is represented by:
[0164]
[0165] Among them, R 1 is selected from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; and R 9 is selected from the group consisting of C1-C3 alkyl, H, and C3-C5 cycloalkyl. 1 CF3; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 is bromine; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 CF2H; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H.
[0166] In some embodiments, the compound is represented by:
[0167]
[0168] Among them, R 1 is selected from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; and R 9 is selected from the group consisting of C1-C3 alkyl, H, and C3-C5 cycloalkyl. 1 CF3; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 is bromine; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 CF2H; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H.
[0169] In some embodiments, the compound is represented by:
[0170]
[0171] Among them, R 1 is selected from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; and R 9 is selected from the group consisting of C1-C3 alkyl, H, and C3-C5 cycloalkyl. 1 CF3; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 is bromine; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H. In some embodiments, R 1 CF2H; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; and R 9 is selected from C1-C3 alkyl and H.
[0172] In some embodiments, the compound is represented by:
[0173]
[0174] Among them, R 1 is selected from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; and R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen. 1 is CF3; and R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine. 1 is bromine; and R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine. 1 is CF2H; and R 2 Selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine.
[0175] In some embodiments, the compound is represented by:
[0176]
[0177] Among them, R 1 is selected from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; and R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen. 1 is CF3; and R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine. 1 is bromine; and R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine. 1 is CF2H; and R 2 Selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine.
[0178] In some embodiments, the compound is represented by:
[0179]
[0180] or a pharmaceutically acceptable salt thereof, wherein: n is 2, 3 or 4; R 1 is selected from the group consisting of halogen, cyano, C1-C5 alkyl and C3-C5 cycloalkyl, wherein each C1-C5 alkyl and C3-C5 cycloalkyl may be optionally substituted with one, two or three independent occurrences of fluorine; R 2 is selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R4 Select from the following group:
[0181] and R 6 and R 9 is independently selected at each occurrence from the group consisting of: H, C1-C6 alkyl, C3-C6 cycloalkyl, C(=O)R 5 、SO2R 5 and D, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; R 5 R is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and heterocyclyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; 7 R is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl and C3-C6 cycloalkyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 7 and the atoms to which they are attached are joined together to form an oxo group; D is selected from a C-linked heterocyclic group and a heteroaryl group having at least one nitrogen and optionally having additional ring nitrogen or oxygen, wherein D may be optionally replaced by R on one or more available carbons 7 substituted and optionally substituted on an available nitrogen by R 9 Substitution; Z is selected from the following group:
[0182]
[0183] and And R 34 independently selected at each occurrence from H and R 36 , where R 36 is independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, wherein each C1-C5 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 36 Joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl group.
[0184] In some embodiments, R 1 Selected from the group consisting of halogen, C 1- C5 alkyl and C 3- C5 cycloalkyl, wherein C 1- The C5 alkyl group may optionally be substituted with one, two or three occurrences of fluorine and C 3- C5 cycloalkyl substituted. In some embodiments, R 1 is CF3. In some embodiments, R 1is CF2H. In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 It is cyclopropyl.
[0185] In some embodiments, R 2 is selected from the group consisting of H, C3-C4 cycloalkyl, C1-C5 alkyl and halogen. 2 Selected from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine.
[0186] In some embodiments, R 4 Select from the following group:
[0187]
[0188] and
[0189] In some embodiments, R 4 Select from the following group:
[0190] and
[0191] In some embodiments, each R 6 and R 9 Independently selected from the group consisting of H, C1-C6 alkyl and C3-C6 cycloalkyl, wherein each of C1-C6 alkyl and C3-C6 cycloalkyl is optionally substituted with one or more independent occurrences of fluorine.
[0192] In some embodiments, R 7 For H.
[0193] In some embodiments, R 34 is selected from the group consisting of H and C1-C5 alkyl, wherein the C1-C5 alkyl may be optionally substituted with one, two or three independent occurrences of fluorine. 34 Joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl group;
[0194] In some embodiments, Z is selected from the group consisting of:
[0195]
[0196] and
[0197]
[0198] In some embodiments, Z is selected from the group consisting of:
[0199]
[0200] and
[0201] In some embodiments, n is 3.
[0202] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0203]
[0204] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 9 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl; 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0205] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0206] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 R is independently selected at each occurrence from H and C1-C3 alkyl; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is independently selected at each occurrence from H and C1-C3 alkyl; each R 34 is H; and n is 3.
[0207] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0208] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0209] and Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl, and C3-C5 cycloalkyl; and n is 3.
[0210] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R at each occurrence is selected from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is selected from H and C1-C3 alkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3.
[0211] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0212]
[0213] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 9 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl; 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0214] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0215] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 R is independently selected at each occurrence from H and C1-C3 alkyl; 34is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is independently selected at each occurrence from H and C1-C3 alkyl; each R 34 is H; and n is 3.
[0216] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0217] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0218] and Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl, and C3-C5 cycloalkyl; and n is 3.
[0219] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R at each occurrence is selected from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is selected from H and C1-C3 alkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from the group consisting of C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from the group consisting of C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3.
[0220] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0221]
[0222] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0223] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0224] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0225] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0226] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0227] and Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3.
[0228] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is selected from C1-C3 alkyl and C3-C4 cycloalkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3.
[0229] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0230]
[0231] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 9 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl; 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0232] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0233] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 R is independently selected at each occurrence from H and C1-C3 alkyl; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is independently selected at each occurrence from H and C1-C3 alkyl; each R 34 is H; and n is 3.
[0234] In some embodiments, R 1 CF2H at each occurrence; R 2R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 is selected at each occurrence from H and C1-C3 alkyl; R 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 9 Each R is selected from H and C1-C3 alkyl at each occurrence; 34 is H; and n is 3.
[0235] In some embodiments, the compound is represented by a formula selected from:
[0236] and Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl, and C3-C5 cycloalkyl; and n is 3.
[0237] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R at each occurrence is selected from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is selected from H and C1-C3 alkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6R is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; 9 is independently selected at each occurrence from H and C1-C3 alkyl; and n is 3.
[0238] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0239]
[0240] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 34 is selected from the group consisting of H, C1-C2 alkyl, and C3-C5 cycloalkyl at each occurrence; and n is 3.
[0241] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 Bromine at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0242] In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0243] In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 34 is independently selected at each occurrence from the group consisting of H and C1-C2 alkyl; and n is 3. In some embodiments, R 1CF2H at each occurrence; R 2 is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; each R 34 is H; and n is 3.
[0244] In some embodiments, the compound is represented by a formula selected from the group consisting of:
[0245]
[0246] Among them, R 1 R is independently selected at each occurrence from the group consisting of bromine, chlorine, CF3, CF2H and cyclopropyl; 2 is independently selected at each occurrence from the group consisting of C1-C2 alkyl, C3-C4 cycloalkyl and halogen; R 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3.
[0247] In some embodiments, R 1 Bromine at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is selected from C1-C3 alkyl and C3-C4 cycloalkyl at each occurrence; and n is 3. In some embodiments, R 1 CF3 at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3. In some embodiments, R 1 CF2H at each occurrence; R 2 R is independently selected at each occurrence from C1-C2 alkyl, C3-C4 cycloalkyl, bromine and chlorine; 6 is independently selected at each occurrence from C1-C3 alkyl and C3-C4 cycloalkyl; and n is 3.
[0248] In one embodiment, described herein is a compound selected from the group consisting of 1-(3-((5-bromo-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-(4-ethylpiperazin-1-yl)-2-methylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((5-chloro-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-cyclopropyl-4-(4-methyl-1,4-diazepan-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((5-chloro-2-((2-methyl-4-(1-methylpiperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, (R)-1-(3-ethyl-4-((4-((3-(2-oxopiperidin-1-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)pyrrolidine-3-carbonitrile, 1-(3-((2-((4-(4-cyclopropylpiperazin-1-yl)-2-methylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((5-bromo-2-((2-isopropyl)piperidin-2-one, propyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-ethyl-4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 4-(3-cyclopropyl-4-((4-((3-(2-oxopiperidin-1-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)-1-methylpiperazin-2-one, 1-( 3-((5-bromo-2-((4-(4-ethylpiperazin-1-yl)-2-isopropylphenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-methyl-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((5-chloro-2-((4-(4-ethylpiperazin-1-yl)-2-isopropylphenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one,1-(3-((2-((2-cyclopropyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-cyclopropyl-5-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-methyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino) propyl)piperidin-2-one, 1-(3-((2-((4-(4-(2-fluoroethyl)piperazin-1-yl)-2-methylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((5-chloro-2-((2-methyl-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-cyclopropylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((5-chloro-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, )amino)propyl)piperidin-2-one, (S)-1-(3-ethyl-4-((4-((3-(2-oxopiperidin-1-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)pyrrolidine-3-carbonitrile, 1-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-(4-isopropylpiperazin-1-yl)-2-methylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)- 5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-(4-cyclobutylpiperazin-1-yl)-2-methylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-cyclopropyl-4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one,1-(3-((2-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-(1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-ethyl-4-(4-methyl-1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-(4-ethylpiperazin-1-yl)-2-isopropylphenyl)amino)-5-( 1-(3-((2-((4-(4-ethyl-1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-methyl-6-morpholinylpyridin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 3-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, -cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((5-chloro-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((5-cyclopropyl-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-cyclopropyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-cyclopropyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((5-bromo-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one,3-(3-((2-((2-methyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, racemic-(R)-3-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)- 1,3-oxazepine-2-one, racemic-(R)-3-(3-((2-((2-cyclopropyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 3-(3-((2-((2-ethyl-4-(4-methyl-2-oxopiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 3-(3-((2-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1 ,3-oxazepan-2-one, 4-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)morpholin-3-one, 1-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azepan-2-one, 4-(3-((2-((2-ethyl-4-morpholinylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-cyclopropyl-4-morpholinylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)morpholin-3-one 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((5-chloro-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one,4-(3-((5-chloro-2-((2-ethyl-4-morpholinylphenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((5-chloro-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((5-chloro-2-((2-cyclopropyl-4-morpholinylphenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((4-(4-ethylpiperazin-1-yl)-2-isopropylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl) -1,4-oxazepan-3-one, 4-(3-((5-cyclopropyl-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-cyclopropyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-ethyl-4-(4-methyl-1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-ethyl-4-(4-methyl-1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-( 4-(3-((5-bromo-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((5-bromo-2-((2-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,4-(3-((2-((2-cyclopropyl-4-morpholinylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-morpholinylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((4-(4-ethylpiperazin-1-yl)-2-isopropylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-methyl-4-(piperazin-1-yl)phenyl)amino) 4-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, racemic-4-(3-((2-((4-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-2-methylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((5-chloro-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((5-bromo-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((5-bromo-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,4-(3-((2-((2-ethyl-5-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((5-bromo-2-((2-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((5-chloro-2-((2-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((5-chloro-2-((2-cyclopropyl -4-(piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, rac-(R)-4-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 1-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 3-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-5-one, -yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 1-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((4-methyl-6-morpholinylpyridin-3-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one,4-(3-((5-chloro-2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl))phenyl)amino)pyridin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 1-(3-((5-cyclopropyl-2-((4-(4-cyclopropylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-5,5-dimethylpyrrolidin-2-one, 1-(3-((2-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((2-methyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl) )amino)propyl)pyrrolidin-2-one, 1-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((4-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, 4-(3-((2-((4-ethyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl) )amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((4-ethyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, (R)-4-(3-((2-((2-cyclopropyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[ 2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 3-(3-((2-((2-ethyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 4-(3-((2-((2-cyclopropyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,3-(3-((2-((2-cyclopropyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 4-(3-((2-((2-ethyl-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-cyclopropyl-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one 1-(3-((2-((2-cyclopropyl-4-(3-(dimethylamino)azetidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 4-(3-((2-((2-ethyl-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 3-(3-((2-((2-ethyl-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 1-(3-((2-((2-cyclopropyl-4-(3-(dimethylamino)azetidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1,4-oxazepan-5-one, 3-(3-((2-((4-ethyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(5-oxo-1,4-oxazepan-4-yl)propyl)amino)pyrimidine-5-carbonitrile, 3-(3-((2-((2-cyclopropyl-4-((1R,4R)-5-methyl-2 , (5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, (S)-2-(4-(3-ethyl-4-((4-((3-(2-oxo-1,3-oxazepan-3-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)-1-methylpiperazin-2-yl)acetonitrile, (R)-2-(4-(3-ethyl-4-((4-((3-(2-oxo-1,3-oxazepan-3-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)-1-methylpiperazin-2-yl)acetonitrile,(S)-2-(1-methyl-4-(3-methyl-4-((4-((3-(5-oxo-1,4-oxazepan-4-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazin-2-yl)acetonitrile, (R)-2-(1-methyl-4-(3-methyl-4-((4-((3-(5-oxo-1,4-oxazepan-4-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazin-2-yl)acetonitrile, 4-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan -5-one, 3-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepan-3-yl)propyl)amino)pyrimidine-5-carbonitrile, 4-(3-((2-((2-ethyl-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-((1R,5 S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-(9-methyl-3,9-diazabicyclo[3.3.1]non-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-(3-methyl-3,9-diazabicyclo[3.3.1]non-9-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one Cycloheptan-5-one, (S)-4-(3-((2-((4-(3-(dimethylamino)pyrrolidin-1-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, (R)-4-(3-((2-((4-(3-(dimethylamino)pyrrolidin-1-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-(1-methylpyrrolidin-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,4-(3-((2-((2-ethynyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-(ethynyl-d5)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-(ethyl-d5)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4- (3-((2-((4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoroethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-(1,1-difluoroethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 5-(4-methylpiperazin-1-yl)-2-((4-((3-(5-oxo-1,4-oxazepan-4-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino) Benzonitrile, 2-methyl-2-(5-(4-methylpiperazin-1-yl)-2-((4-((3-(5-oxo-1,4-oxazepan-4-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)propionitrile, 2-(5-(4-methylpiperazin-1-yl)-2-((4-((3-(5-oxo-1,4-oxazepan-4-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)acetonitrile, 4-(3-((2-((4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4 -oxazepan-5-one, 4-(3-((2-((2-(difluoromethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-bromo-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,4-(3-((2-((2-cyclopropyl-4-(3-(dimethylamino)azetidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-cyclopropyl-4-(3-((dimethylamino)methyl)azetidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 1-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3-methyltetrahydropyrimidin-2 (1H)-one, 1-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3-methyltetrahydropyrimidin-2(1H)-one, 3-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 1-( 3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-4-methyl-1,4-diazepan-2-one, 1-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-4-methyl-1,4-diazepan-2-one, 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methyl-1,4-diazepan-5-one, 4- (3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methyl-1,4-diazepan-5-one, 1-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3-methyl-1,3-diazepan-2-one, 1-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3-methyl-1,3-diazepan-2-one,3-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 3-(3-((5-(difluoromethyl)-2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 3-(3-((2-((2-cyclopropyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)- 5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 3-(3-((5-(difluoromethyl)-2-((2-ethyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 3-(3-((5-(difluoromethyl)-2-((2-ethyl-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, (R) -3-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, (S)-3-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3 -oxazepine-2-one, 3-(3-((2-((2-cyclopropyl-4-(piperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 1-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-3-methyltetrahydropyrimidin-2(1H)-one, 1-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-3-methyltetrahydropyrimidin-2(1H)-one,4-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 3-(3-( (5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 1-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-4-methyl-1,4-diazepan-2-one, 1-(3-((2 -((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-4-methyl-1,4-diazepan-2-one, 4-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1-methyl-1,4-diazepan-5-one, 4-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-1-methyl-1,4-diazepan-5-one 、1-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-3-methyl-1,3-diazepan-2-one、1-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-3-methyl-1,3-diazepan-2-one、2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepan-3-yl)propyl)amino)pyrimidine-5-carbonitrile、2-((2-cyclopropyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino )-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile, (R)-2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile, (S)-2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazine-2(1H)-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile [1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-(piperazin-1-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-cyclopropyl-4-(piperazin-1-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepine-3-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(3-methyl-2- 2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(3-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(3-oxo-1,4-oxazepan-4-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(3-oxo-1,4-oxazepan-4-yl)propyl)amino)pyrimidine-5-carbonitrile,2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(5-oxo-1,4-oxazepan-4-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepan-3-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(2-oxo-1,3-oxazepan-3-yl)propyl)amino)pyrimidine-5-carbonitrile, -((3-(4-methyl-2-oxo-1,4-diazepan-1-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(4-methyl-7-oxo-1,4-diazepan-1-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(4-methyl-7-oxo-1,4-diazepan-1-yl)propyl)amino)pyrimidine-5-carbonitrile, 2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(3-methyl-2-oxo-1,4-diazepan-1-yl)phenyl)amino)-4-((3-(4-methyl-7-oxo-1,4-diazepan-1-yl)propyl)amino)pyrimidine-5-carbonitrile, 3-((2-cyclopropyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-((3-(3-methyl-2-oxo-1,3-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-cyclopropyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-6,6-dimethyl-1,3-oxazepan-2-one, 4-(3-((2-((2-cyclopropyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,4-(3-((2-((2-cyclopropyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((5-(difluoromethyl)-2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo 4-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one Azepan-3-one, 4-(3-((2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 3-(3-((5-(difluoromethyl)-2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl- 3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-6,6-dimethyl-1,4-oxazepan-5-one, 3-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-6,6-dimethyl-1,3-oxazepan-2-one,4-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-2,2-dimethyl-1,4-oxazepan-3-one, 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-2,2-dimethyl-1,4-oxazepan-3-one, 4-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino) propyl)-6,6-dimethyl-1,4-oxazepan-5-one, 8-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-5-oxa-8-azaspiro[2.6]nonan-9-one, 4-(3-((2-((4-(1,4-diazabicyclo[3.2.1]octan-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3- 4-(3-((5-(difluoromethyl)-2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)-6,6-dimethyl-1,4-oxazepan-5-one, 4-(3-((2-((4-(1,4-diazabicyclo[3.2.1]oct-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-6,6-dimethyl-1,4-oxazepan-5-one Heterocycloheptan-5-one, 4-(3-((2-((4-(1,4-diazabicyclo[3.2.1]octan-4-yl)-2-ethylphenyl)amino)-5-(difluoromethyl)pyrimidin-4-yl)amino)propyl)-6,6-dimethyl-1,4-oxazepan-5-one, 1-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidin-2-one, 1-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3,3-dimethylazetidin-2-one,1-(3-((2-((4-(1,4-diazabicyclo[3.2.1]oct-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidin-2-one, 1-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidin-2-one, 1-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidin-2-one )pyrimidin-4-yl)amino)propyl)-3,3-dimethylazetidin-2-one, 1-(3-((2-((4-(1,4-diazabicyclo[3.2.1]octan-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3,3-dimethylazetidin-2-one, 1-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidin-2-one, 1-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidin-2-one, )phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3,3-dimethylazetidin-2-one, 1-(3-((2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azetidin-2-one, 1-(3-((2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3,3-dimethylazetidin-2-one, 1-(3-((2-((2-ethyl-4 -(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-3,3-dimethylpyrrolidin-2-one,1-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((5-(difluoromethyl)-2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one )pyrimidin-4-yl)amino)propyl)-3,3-dimethylpyrrolidin-2-one, 1-(3-((2-((4-(1,4-diazabicyclo[3.2.1]oct-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((4-(1,4-diazabicyclo[3.2.1]oct-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((4-(1,4-diazabicyclo[3.2.1]oct-4-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((5-(difluoromethyl)-2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)- 3,3-dimethylpyrrolidin-2-one, 1-(3-((5-chloro-2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((5-chloro-2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((4-(1,4-diazabicyclo[3.2.1]oct-4-yl)-2-ethylphenyl)amino)-5-chloropyrimidin-4-yl)amino)propyl)pyrrolidin-2-one,1-(3-((5-chloro-2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((5-bromo-2-((2-ethyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((5-bromo-2-((2-ethyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((2-((4 -(1,4-diazabicyclo[3.2.1]octan-4-yl)-2-ethylphenyl)amino)-5-bromopyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 1-(3-((5-bromo-2-((2-ethyl-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-one, 4-(3-((2-((4-(3-(diethylamino)propyl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-cyclopropyl-4-(3-morpholinopropyl)phenyl)amino)-5-(trifluoromethyl) 3-(3-((2-((2-ethyl-4-(2-(pyrrolidin-1-yl)ethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-cyclopropyl-4-((dimethylamino)methyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-cyclopropyl-4-(4-methylpiperazine-1-carbonyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one Hexan-2-one, 3-methoxy-N-(1-methylpiperidin-4-yl)-4-((4-((3-(5-oxo-1,4-oxazepan-4-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide, 4-(3-((2-((4-(4-(diethylamino)piperidin-1-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, (S)-4-(3-((2-((2-cyclopropyl-4-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,1-(3-((2-((2-cyclopropyl-4-(morpholinylmethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-ethyl-4-(2-(pyrrolidin-1-yl)propan-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 4-(3-((2-((2-ethyl-4-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((4-(4-((dimethylamino)methyl)piperidin-1-yl)- 2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((4-(4-(dimethylglycyl)piperazin-1-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((4-(3,3-dimethylpiperazin-1-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((4-(3,3-dimethylpiperazin-1-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-ethyl-4-(3,3,4-trimethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-cyclopropyl-4-(3,4,5-trimethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-ethyl-4-(3,3,4-trimethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-ethyl-4-(3,3,4,5,5-pentamethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, )amino)propyl)-1,4-oxazepan-3-one, 1-(3-((2-((2-chloro-4-(3,4-dimethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)azepan-2-one, 3-(3-((2-((4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 4-(3-((2-((4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-3-one,4-(3-((2-((4-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 3-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 4-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 1,4-oxazepan-5-one, 3-(3-((2-((2-bromo-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 4-(3-((2-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 1-(3-((2-((4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)azepan-2-one, 1-(3-((2-((2-cyclopropyl-4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)pyrrolidine-5-one 2-one, 4-(3-((2-((4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-methyl-4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((4-(4-(dimethylglycyl)piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepan-5-one,3-(3-((2-((2-ethyl-4-(4-methylpiperazine-1-carbonyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 1-(3-((2-((2-cyclopropyl-4-(morpholinylmethyl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, 3-(3-((2-((2-ethyl-4-(2-(pyrrolidin-1-yl)ethyl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-fluoro-4-(3-morpholinylpropyl)phenyl)amino)- 1-(3-((2-((2-cyclopropyl-4-((1,1-dioxothiomorpholinyl)methyl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, 1-(3-((2-((2-cyclopropyl-4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, 3-(3-((2-((4-(3-(diethylamino)propyl)-2-(trifluoromethyl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1-(3-((2-((2-cyclopropyl-4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, ,3-oxazepine-2-one, 4-(3-((2-((2-chloro-4-(3,4-dimethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)-1,4-oxazepine-5-one, 1-(3-((2-((2-cyclopropyl-4-(morpholinylsulfonyl)phenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one, 3-(3-((2-((2-(2-hydroxypropan-2-yl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 4-(3-((2-((2 -(2-hydroxypropan-2-yl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-(1-hydroxyethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-methyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,4-(3-((2-((2-chloro-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-(1-hydroxyethyl)-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-methyl-4-((1S,4S)-5-methyl-2,5- 4-(3-((2-((2-chloro-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-chloro-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, -yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-methyl-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-chloro-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-(1-hydroxy-4-((1-hydroxy-4-((1-hydroxy-4-((1-hydroxy-4-((1-hydroxy-4-( 1,4-oxazepan-5-one, 3-(3-((2-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-(1-hydroxyethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one,3-(3-((2-((2-chloro-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-(1-hydroxyethyl)-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-methyl-4-((1S,4S)-5-methyl-2,5 -diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-chloro-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-(1-hydroxyethyl)-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 1,3-oxazepine-2-one, 3-(3-((2-((2-methyl-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 3-(3-((2-((2-chloro-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, 3-(3-((2-((2-chloro-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepine-2-one, (1-hydroxyethyl)-4-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 4-(3-((2-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one,4-(3-((2-((2-(1-hydroxyethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-methyl-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-chloro-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)- 5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((2-(1-hydroxyethyl)-4-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-3-one, 4-(3-((2-((4-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 4-(3-((2-((2-(difluoromethoxy)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, )-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 3-(3-((2-((2-(methoxymethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,3-oxazepan-2-one, 3-(3-((2-((2-cyclopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-6,6-dimethyl-1,3-oxazepan-2-one, 4-(3-((2-((4-((1 R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, 1-(3-((2-((2-cyclopropyl-4-(3-((dimethylamino)methyl)azetidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one, 4-(3-((2-((4-(3-((dimethylamino)methyl)azetidin-1-yl)-2-ethylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one,4-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one, and pharmaceutically acceptable salts, enantiomers, stereoisomers and tautomers thereof.
[0249] Treatment
[0250] The compounds described herein can act as autophagy inhibitors useful for treating a disorder in a patient in need thereof. For example, the disorder can be a tumor such as a solid tumor. The disorder can also be cancer.
[0251] Exemplary disorders also include gastrointestinal stromal tumors, esophageal cancer, gastric cancer, melanoma, glioma, glioblastoma, ovarian cancer, bladder cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, kidney cancer, liver cancer, osteosarcoma, multiple myeloma, cervical cancer, bone metastases, papillary thyroid cancer, non-small cell lung cancer and colorectal cancer. The cancer treated by the methods described herein can be a metastatic cancer.
[0252] In some embodiments, the compounds described herein can be used to treat cancers caused by RAS mutations. In some embodiments, the cancer is caused by KRAS mutations. In some embodiments, the cancer has additional mutations in tumor suppressor proteins, including TP53, PTEN, CDN2A / INK4A, p16, or STAG2 mutations. In some embodiments, these additional mutations occur in one or more of TP53, PTEN, CDN2A / INK4A, p16, or STAG2. In some embodiments, the cancer is pancreatic ductal adenocarcinoma. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is colorectal cancer.
[0253] In some embodiments, the determination of the autophagic cell inhibition performed by the compounds described herein is by monitoring autophagic flux, for example, by monitoring the inhibition of the removal of the mCherry / GFP-LC3 fusion protein mediated by autophagy. In some embodiments, the determination of the autophagic cell inhibition performed by the compounds described herein is by monitoring the accumulation of autophagic proteins such as p62 or LC-3. In some embodiments, the determination of the autophagic cell inhibition performed by the compounds described herein is by the removal of the reduced LC3 protein with luciferase label. In some embodiments, the determination of the autophagic cell inhibition performed by the compounds described herein is by monitoring the reduction of the cell autophagosome, for example, by measuring the fluorescent spots with the autophagosome marker Cyto-ID.
[0254] In some embodiments, ULK kinase cellular inhibition by the compounds described herein is measured by inhibition of phosphorylation of cellular ULK substrates including ATG13, ATG14, Beclin 1 or STING in tumor cells or non-tumor host tissues. In some embodiments, ULK kinase cellular inhibition by the compounds described herein is measured in host tissues including immune cells.
[0255] In some embodiments, the in vivo inhibition of autophagy by the compounds described herein is determined by the inhibition of phosphorylation of cellular ULK substrates including ATG13, ATG14, Beclin 1 or STING in tumor cells or non-tumor host tissues. In some embodiments, the in vivo inhibition of ULK kinase by the compounds described herein is determined in host tissues including immune cells. In some embodiments, the in vivo inhibition of autophagy by the compounds described herein can be used as a pharmacokinetic model for monitoring the kinetics and extent of the ULK inhibition. In some embodiments, the in vivo inhibition of ULK kinase by the compounds described herein is determined in animals with pancreatic cancer. In some embodiments, the in vivo inhibition of ULK kinase by the compounds described herein is determined in animals with lung cancer. In some embodiments, the in vivo inhibition of ULK kinase by the compounds described herein is determined in animals with colorectal cancer. In some embodiments, the in vivo inhibition of autophagy by the compounds described herein is determined by the inhibition of autophagic flux in tumor cells or non-tumor host tissues using the inhibition of monitoring autophagosome formation or by the accumulation of autophagic proteins such as p62 or LC-III. In some embodiments, in vivo inhibition of autophagy is determined in host tissues including immune cells. In some embodiments, in vivo inhibition of autophagy can be used as a pharmacokinetic model for monitoring the kinetics and extent of ULK inhibition.
[0256] In some embodiments, the autophagy inhibition and anti-tumor activity performed by the compounds described herein are evaluated in xenograft studies using human RAS mutant cell lines in immunocompromised mice such as SCID or nude mice. In some embodiments, the autophagy inhibition and anti-tumor activity performed by the compounds described herein are evaluated in xenograft studies using tumor xenografts (PDX) derived from human RAS mutant patients in immunocompromised mice such as SCID or nude mice. In some embodiments, xenograft studies include the evaluation of the compounds described herein in pancreatic cancer models. In some embodiments, the autophagy inhibition and anti-tumor activity performed by the compounds described herein are evaluated in genetically engineered models (GEMs) of isogenic mice with mutant RAS cancer. In some embodiments, the autophagy inhibition and anti-tumor activity performed by the compounds described herein are evaluated in the mouse GEM isogenic orthotopic pancreatic cancer model referred to as the following: KPC model (LSL-Kras G12D / + ;LSL-Trp53 R172H / + ; Pdx-1-Cre) or KPC model variants.
[0257] In some embodiments, the compounds described herein are evaluated in combination with MEK inhibitors in xenograft or GEM cancer models. In some embodiments, the compounds described herein are evaluated in combination with RAF inhibitors in xenograft or GEM cancer models. In some embodiments, the compounds described herein are evaluated in combination with ERK inhibitors in xenograft or GEM cancer models. In some embodiments, the compounds described herein are evaluated in combination with RAS G12C direct inhibitors in xenograft or GEM cancer models.
[0258] In some embodiments, autophagy inhibition and anti-tumor activity by the compounds described herein are evaluated in an immunocompetent mouse cancer model to assess the immunomodulatory component of the mechanism of action of the ULK inhibitor. In some embodiments, the immunocompetent mouse model is a mouse GEM syngeneic orthotopic pancreatic cancer model referred to as the KPC model (LSL-Kras G12D / + ;LSL-Trp53 R172H / + ; Pdx-1-Cre) or KPC model variants. In some embodiments, the immunomodulatory properties of the compounds described herein are evaluated in conjunction with MEK inhibitors. In some embodiments, the immunomodulatory properties of the compounds described herein are evaluated in conjunction with RAF inhibitors. In some embodiments, the immunomodulatory properties of the compounds described herein are evaluated in conjunction with ERK inhibitors. In some embodiments, the immunomodulatory properties of the compounds described herein are evaluated in conjunction with RAS G12C direct inhibitors.
[0259] In some embodiments, the immunomodulatory component of ULK inhibition is an enhanced innate immune response. In some embodiments, the immunomodulatory component of ULK inhibition is an enhanced adaptive immune response. In some embodiments, the immunomodulatory component of ULK inhibition is an enhanced activity of antigen presenting cells. In some embodiments, the immunomodulatory component of ULK inhibition is an enhanced anti-tumor activity of myeloid cells including macrophages. In some embodiments, the immunomodulatory component of ULK inhibition is an enhanced anti-tumor activity of natural killer cells. In some embodiments, the immunomodulatory component of ULK inhibition is an enhanced activity of effector T cells including cytotoxic T cells.
[0260] In some embodiments, provided herein is a method for treating a condition described herein, comprising: administering a therapeutically effective amount of a compound described herein in a patient in need thereof, and detecting the binding of the compound to ULK kinase during or after the administration process (e.g., at discrete time points, such as one week, two weeks, or one month after the initial administration of the compound under consideration), wherein the detection comprises contacting a sample obtained from the patient (including but not limited to a tumor, blood, saliva, or tissue) with a phosphorylated ATG13 antibody ELISA assay to, for example, detect ULK kinase activity inhibition based on the content of phosphorylated ATG13 in the sample. In some embodiments, the method contemplated comprises contacting a sample obtained from the patient (including but not limited to a tumor, blood, saliva, or tissue) with a phosphorylated ATG13 antibody ELISA assay, optionally before administering the compound, and comparing the phosphorylated ATG13 level in the sample obtained before administration with the phosphorylated ATG13 level in the sample obtained during or after the administration process. In some embodiments, phosphorylated ATG13 is p-S318ATG13.
[0261] In some embodiments, provided herein are methods for treating the disorders described herein, comprising: administering a therapeutically effective amount of a compound described herein in a patient in need thereof, and detecting the binding of the compound to ULK kinase during or after the administration process (e.g., at discrete time points, such as one week, two weeks, or one month after the initial administration of the compound under consideration), wherein the detection comprises contacting a sample obtained from the patient (including but not limited to a tumor, blood, saliva, or tissue) with a phosphorylated ATG14 antibody ELISA assay to, for example, detect ULK kinase activity inhibition based on the content of phosphorylated ATG14 in the sample. In some embodiments, the contemplated method comprises contacting a sample obtained from the patient (including but not limited to a tumor, blood, saliva, or tissue) with a phosphorylated ATG14 antibody ELISA assay, optionally before administering the compound, and comparing the phosphorylated ATG14 content in the sample obtained before administration with the phosphorylated ATG14 content in the sample obtained during or after the administration process. In some embodiments, phosphorylated ATG14 is p-ATG14 Ser29.
[0262] In some embodiments, provided herein are methods for treating a disorder described herein, comprising: administering a therapeutically effective amount of a compound described herein in a patient in need thereof, and detecting the binding of the compound to ULK kinase during or after the administration process (e.g., at discrete time points, such as one week, two weeks, or one month after the initial administration of the compound under consideration), wherein the detection comprises contacting a sample obtained from the patient (including but not limited to a tumor, blood, saliva, or tissue) with a p62 antibody ELISA assay to detect, for example, inhibition of ULK kinase activity based on the amount of p62 in the sample. In some embodiments, the contemplated method comprises contacting a sample obtained from the patient (including but not limited to a tumor, blood, saliva, or tissue) with a p62 antibody ELISA assay, optionally prior to administering the compound, and comparing the amount of p62 in the sample obtained before administration with the amount of p62 in the sample obtained during or after the administration process.
[0263] In some embodiments, provided herein are methods for treating a condition described herein, comprising: administering a therapeutically effective amount of a compound described herein to a patient in need thereof, and detecting binding of the compound to ULK kinase during or after the administration process (e.g., at discrete time points, such as one week, two weeks, or one month after the initial administration of the compound under consideration), wherein the detection comprises contacting a sample obtained from the patient (including but not limited to a tumor, blood, saliva, or tissue) with a pBeclin antibody ELISA assay to detect inhibition of ULK kinase activity, for example, based on the amount of pBeclin in the sample. In some embodiments, the contemplated method comprises contacting a sample obtained from the patient (including but not limited to a tumor, blood, saliva, or tissue) with a pBeclin antibody ELISA assay, optionally prior to administering the compound, and comparing the amount of pBeclin in the sample obtained prior to administration with the amount of pBeclin in the sample obtained during or after the administration process.
[0264] The compounds provided herein can provide the dosage of the best medical efficacy for administration to patients (animals and humans) in need of the treatment. It should be understood that the dosage required for use in any particular application will vary with the patient, not only with the selected specific compound or composition, but also with the route of administration, the nature of the condition to be treated, the age and condition of the patient, the simultaneous drug treatment or the special diet followed by the patient, and other factors recognized by those skilled in the art, wherein the appropriate dose is ultimately determined by the attending physician. For the treatment of the clinical conditions and diseases mentioned above, the compounds provided herein can be administered orally, subcutaneously, topically, parenterally, by inhalation spray or rectally in the form of dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Parenteral administration may include subcutaneous injection, intravenous or intramuscular injection or infusion techniques.
[0265] Treatment can be continued for a long period of time or a short period of time as needed. The composition can be administered according to a regimen of, for example, one to four times a day or more. A suitable treatment period can be, for example, at least about one week, at least about two weeks, at least about one month, at least about six months, at least about 1 year, or an indefinite period of time. The treatment period can be terminated when the desired result is achieved.
[0266] Combination therapy
[0267] Compounds described herein, such as compounds of formula I as defined herein, can be administered in combination with one or more additional therapeutic agents to treat conditions described herein, such as cancer. For example, the present invention provides pharmaceutical compositions comprising compounds described herein, such as compounds of formula I as defined herein, one or more additional therapeutic agents, and pharmaceutically acceptable excipients. In some embodiments, a compound of formula I as defined herein and one additional therapeutic agent are administered. In some embodiments, a compound of formula I as defined herein and two additional therapeutic agents are administered. In some embodiments, a compound of formula I as defined herein and three additional therapeutic agents are administered. Combination therapy can be achieved by administering two or more therapeutic agents, each of which is separately formulated and administered. For example, a compound of formula I as defined herein and an additional therapeutic agent can be separately formulated and administered. Combination therapy can also be achieved by administering two or more therapeutic agents in a single formulation, which, for example, comprises a pharmaceutical composition of a compound of formula I as a therapeutic agent and one or more additional therapeutic agents such as a MAPKAP pathway inhibitor or a chemotherapeutic agent. For example, the compound of formula I as defined herein and additional therapeutic agents can be administered in a single formulation. Combination therapy also encompasses other combinations. Although two or more agents in combination therapy can be administered simultaneously, this is not necessarily the case. For example, the administration of the first agent (or combination of agents) can be several minutes, hours, days or weeks ahead of the administration of the second agent (or combination of agents). Therefore, the administration of two or more agents can be within a few minutes of each other, or within 1, 2, 3, 6, 9, 12, 15, 18 or 24 hours of each other, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 days, or within 2, 3, 4, 5, 6, 7, 8, 9 weeks or weeks of each other. In some cases, even longer time intervals are possible. Although in many cases, the two or more agents used in combination therapy need to be present in the patient's body at the same time, this is not necessarily the case.
[0268] Combination therapy may also include two or more administrations of one or more of the agents used in combination using different orderings of the component agents. For example, if agent X and agent Y are used in combination, they may be administered one or more times in any combination in sequence, such as in the order of XYX, XXY, YXY, YYX, XXYY, etc.
[0269] In some embodiments, one or more additional therapeutic agents that can be administered in combination with the compounds provided herein can be MAPKAP pathway inhibitors. Such MAPKAP pathway inhibitors include, for example, MEK inhibitors, ERK inhibitors, RAF inhibitors, and Ras inhibitors.
[0270] Exemplary MEK inhibitors include, but are not limited to, trametinib, selumetinib, cobimetinib, bimetinib, and pharmaceutically acceptable salts thereof. Exemplary ERK inhibitors include, but are not limited to, uritinib, SCH772984, LY3214996, ravoxertinib, VX-11e, and pharmaceutically acceptable salts thereof. Exemplary RAF inhibitors include, but are not limited to, LY3009120, LXH254, RAF709, dabrafenib, vemurafenib, and pharmaceutically acceptable salts thereof. Exemplary Ras inhibitors include, but are not limited to, AMG-510, MRTX849, and pharmaceutically acceptable salts thereof.
[0271] Compounds described herein can be administered in combination with other therapeutic agents known for treating cancer. Such other therapeutic agents include radiotherapy, anti-tubulin agents, DNA alkylating agents, DNA synthesis inhibitors, DNA intercalators, antiestrogens, anti-androgens, steroids, anti-EGFR agents, kinase inhibitors, mTOR inhibitors, PI3 kinase inhibitors, cyclin-dependent kinase inhibitors, CD4 / CD6 kinase inhibitors, topoisomerase inhibitors, histone deacetylase (HDAC) inhibitors, DNA methylation inhibitors, anti-HER2 agents, anti-angiogenic agents, proteasome inhibitors, PARP inhibitors, cell cycle regulation kinase inhibitors, thalidomide, lenalidomide, antibody-drug conjugates (ADC), immunotherapeutics including immunomodulators, targeted therapeutics, cancer vaccines and CAR-T cell therapies.
[0272] In one embodiment, the additional therapeutic agent can be a chemotherapeutic agent including, but not limited to, an anti-tubulin agent (e.g., paclitaxel, paclitaxel protein-bound particles for injectable suspension including nab-paclitaxel, eribulin, docetaxel, ixabepilone, vincristine, auristatins, or maytansines), vinorelbine, a DNA alkylating agent (including cisplatin, carboplatin, oxaliplatin, cyclophosphamide, ifosfamide, temozolomide), a DNA intercalator, or a DNA topoisomerase inhibitor (including anthracyclines anthracyclines such as doxorubicin, pegylated liposomal doxorubicin, daunorubicin, idarubicin, mitoxantrone, or epirubicin; camptothecins such as topotecan, irinotecan, or exatecan), 5-fluorouracil, capecitabine, cytarabine, decitabine, 5-azacytidine, gemcitabine, and methotrexate.
[0273] In some other embodiments, the additional therapeutic agent may be a kinase inhibitor including, but not limited to, erlotinib, gefitinib, neratinib, afatinib, osimertinib, lapatanib, crizotinib, brigatinib, ceritinib, alectinib, lorlatinib, everolimus, temsirolimus, us), abemaciclib, LEE011, palbociclib, cabozantinib, sunitinib, pazopanib, sorafenib, regorafenib, sunitinib, axitinib, dasatinib, imatinib, nilotinib, idelalisib, ibrutinib, BLU-667, Loxo 292. larotrectinib and quizartinib; antiestrogens including but not limited to the following: tamoxifen, fulvestrant, anastrozole, letrozole and exemestane; antiandrogens including but not limited to the following: abiraterone acetate, enzalutamide, nilutamide, bicalutamide, flutamide, cyproterone acetate, acetate); steroid agents including but not limited to the following: prednisone and dexamethasone; PARP inhibitors including but not limited to the following: neraparib, olaparib, talazoparib and rucaparib; topoisomerase I inhibitors including but not limited to the following: irinotecan, camptothecin, exinotecan and topotecan; topoisomerase II inhibitors including but not limited to the following: anthracyclines, etoposide, etoposide phosphate and mitoxantrone;Including but not limited to the following histone deacetylase (HDAC) inhibitors: vorinostat, romidepsin, panobinostat, valproic acid and belinostat; including but not limited to the following DNA methylation inhibitors: DZNep and 5-aza-2'-deoxycytidine; including but not limited to the following proteasome inhibitors: bortezomib and carfilzomib; thalidomide; lenalidomide; pomalidomide; including but not limited to the following biological agents: trastuzumab, ado-trastuzumab, pertuzumab, cetuximab, panitumu mab), ipilimumab, tremelimumab; anti-PD-1 agents including the following: pembrolizumab, nivolumab, pidilizumab, and cemiplimab; anti-PD-L1 agents including the following: atezolizumab, avelumab, durvalumab, and BMS-936559; anti-angiogenic agents including the following: bevacizumab and aflibercept; and antibody-drug conjugates (ADCs) including the following: DM1, DM4, MMAE, MMAF, or camptothecin payloads; brentuximab vedotin and trastuzumab emtansine; radiation therapy; therapeutic vaccines including but not limited to sipuleucel-T. ;
[0274] In some embodiments, the additional therapeutic agent may be an immunomodulator including but not limited to the following: anti-PD-1 or anti-PDL-1 therapeutic agents, including pembrolizumab, nivolumab, atezolizumab, durvalumab, BMS-936559 or avelumab; anti-TIM3 (anti-HAVcr2) therapeutic agents, including but not limited to TSR-022 or MBG453; anti-LAG3 therapeutic agents, including but not limited to relatlimab, LAG525 or TSR-033; anti-4-1BB (anti-CD37, anti-TNFRSF9) drugs; CD40 agonist therapeutic agents, including but not limited to SGN-40, CP-870 ,893 or RO7009789; anti-CD47 therapeutic agents, including but not limited to Hu5F9-G4; anti-CD20 therapeutic agents; anti-CD38 therapeutic agents; STING agonists, including but not limited to ADU-S100, MK-1454, ASA404 or amidobenzimidazoles; anthracyclines, including but not limited to cranberries or mitoxantrone; hypomethylating agents, including but not limited to azacytidine or decitabine; other immunomodulatory therapeutic agents, including but not limited to epidermal growth factor inhibitors, statins, metformin, angiotensin receptor blockers, thalidomide, lenalidomide, polydimide, prilocaine or dexamethasone.
[0275] In some embodiments, the additional therapeutic agent is selected from the group consisting of luteinizing hormone releasing hormone (LHRH) analogs including goserelin and leuprolide.
[0276] In some embodiments, the additional therapeutic agent is selected from the group consisting of everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-e tu), nolatrexed, azd2171, batabulin, ofatumtunab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdR1KRX-0402, lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, cranberry, irinotecan, liposomal cranberry, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib;PD0325901, AZD-6244, capecitabine, L-glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-ethyl]benzoyl]-, disodium salt heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES (diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258); 3-[5-(methylsulfonylpiperidinylmethyl)-indolyl]-quinolinone, vatalanib, AG-013736, AVE-0005, [D-Ser(Bu t)6, Azgly 10] acetate (pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu t)-Leu-Arg-Pro-Azgly-NH2 acetate [C; 59 H 84 N 18 Oi4-(C2H4O2) x, wherein x = 1 to 2.4], goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate caproate), megestrolacetate, raloxifene, bicalutamide, flutanide, nilutamide, megestrolacetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatinib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW-572016, lonafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoylanilide hydroxamic acid, valproic acid, trichostatin A A), FK-228, SU11248, sorafenib, KRN951, aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-GuérinCalmette-Guerin, BCG), bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunomycin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gemcitabine, gleevac, hydroxyurea, edamycin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, thamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deoxyuridine, cytosine arabinoside,arabinoside, 6-mercaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox), gefitinib, bortezimib, irinotecan, topotecan, cranberry, docetaxel, vinorelbine, bevacizumab (monoclonal antibody) and erbitux, cremophor-free paclitaxel, epothilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339, ZK186619, PTK787 / ZK222584, VX-745, PD184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prilocaine, cetuximab, granulocyte Macrophage colony-stimulating factor, histrelin, pegylated interferon alpha-2a, interferon alpha-2a, pegylated interferon alpha-2b, interferon alpha-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-trans retinoic acid, ketoconazole, interleukin-2, megestrol acetate, immune globulin, nitrogen mustard, methylprednisolone, ibrigtumomab tiuxetan), androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, alendronate, mitotane, cyclosporine, liposomaldaunorubicin, Edwina-asparaginase, strontium 89, casopitant asopitant), netupitant, NK-1 receptor antagonist, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dexamethasone, methylprednisolone, prochlorperazine prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa and darbepoetin alfa, ipilumumab, vemurafenib, and mixtures thereof.
[0277] Pharmaceutical compositions and kits
[0278] Another aspect of the present invention provides a pharmaceutical composition comprising a compound as disclosed herein formulated with a pharmaceutically acceptable carrier. Specifically, the present invention provides a pharmaceutical composition comprising a compound as disclosed herein formulated with one or more pharmaceutically acceptable carriers. These formulations include formulations suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal or intravenous), rectal, vaginal or aerosol administration, but in any given case, the most suitable form of administration will depend on the degree and severity of the condition being treated and on the properties of the specific compound used. For example, the disclosed composition can be formulated in unit dosage form, and / or can be formulated for oral or subcutaneous administration.
[0279] Exemplary pharmaceutical compositions can be used in the form of pharmaceutical preparations, such as solid, semisolid or liquid forms, which contain as active ingredients one or more of the compounds described herein in admixture with organic or inorganic carriers or excipients suitable for external, enteral or parenteral application. The active ingredients can be mixed, for example, with conventional non-toxic, pharmaceutically acceptable carriers for tablets, pills, capsules, suppositories, solutions, emulsions, suspensions and any other suitable use forms. The active target compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect on the disease process or condition.
[0280] For preparing solid compositions such as tablets, the main active ingredient can be mixed with a pharmaceutical carrier such as conventional tableting ingredients (such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums) and other pharmaceutical diluents such as water to form a solid preformulation composition containing a homogeneous mixture of the compound provided herein or a non-toxic, pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous preformulation compositions, it is meant that the active ingredient is evenly dispersed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
[0281] In a solid dosage form for oral administration (capsule, tablet, pill, dragee, powder, granule, etc.), the composition of the present invention is mixed with one or more pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate and / or any of the following: (1) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) binders such as carboxymethylcellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose and / or gum arabic; (3) humectants , such as glycerol; (4) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; (5) solution retardants, such as paraffin; (6) absorption promoters, such as quaternary ammonium compounds; (7) wetting agents, such as acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the composition may also contain a buffer. Solid compositions of a similar type may also be used as fillers in soft-filled and hard-filled gelatin capsules using excipients such as lactose (lactose / milk sugar) and high molecular weight polyethylene glycols.
[0282] Tablets can be made by compression or molding, optionally with one or more compounding agents. Compressed tablets can be prepared using a binder (e.g., gelatin or hydroxypropylmethylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), a surfactant, or a dispersant. Molded tablets can be made by molding a mixture of the composition of the present invention moistened with an inert liquid diluent in a suitable machine. Tablets and other solid dosage forms such as dragees, capsules, pills, and granules can be optionally scored or prepared with coatings and shells such as enteric coatings and other coatings known in the art of pharmaceutical formulation.
[0283] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the composition, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents; solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (specifically, cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuran methanol, polyethylene glycol and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof.
[0284] Suspensions, in addition to the compositions of the present invention, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0285] Formulations for rectal or vaginal administration may be presented in the form of suppositories which may be prepared by mixing the compositions of the present invention with one or more suitable non-irritating excipients or carriers including, for example, cocoa butter, polyethylene glycol, suppository wax or salicylates and which are solid at room temperature but liquid at body temperature and therefore will melt in the body cavity and release the active agent.
[0286] Dosage forms for transdermal administration of the compositions of the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active ingredient may be mixed under sterile conditions with a pharmaceutically acceptable carrier and with any preservatives, buffers or propellants that may be required.
[0287] Ointments, pastes, creams and gels may contain, in addition to the compositions of the present invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0288] In addition to the compositions of the present invention, powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants such as chlorofluorocarbons and volatile unsubstituted hydrocarbons (such as butane and propane).
[0289] The compositions and compounds of the present invention may alternatively be administered by aerosol. This is achieved by preparing an aqueous aerosol, liposomal formulation or solid particles containing the compound. Non-aqueous (e.g., fluorocarbon propellant) suspensions may be used. Sonic nebulizers may be used because they minimize exposure of the agent to shear forces that may cause degradation of the compounds contained in the compositions of the present invention. Typically, aqueous aerosols are prepared by formulating an aqueous solution or suspension of the composition of the present invention with conventional pharmaceutically acceptable carriers and stabilizers. Carriers and stabilizers vary with the requirements of the particular composition of the present invention, but typically include nonionic surfactants (Tweens, Pluronics or polyethylene glycols); harmless proteins such as serum albumin; sorbitan esters; oleic acid; lecithin; amino acids such as glycine; buffers; salts; sugars or sugar alcohols. Aerosols are generally prepared from isotonic solutions.
[0290] Pharmaceutical compositions of the present invention suitable for parenteral administration comprise a composition of the present invention and one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions or sterile powders which can be reconstituted into sterile injectable solutions or dispersions immediately before use, such sterile powders may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient, or suspending agents or thickening agents.
[0291] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions provided herein include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate) and cyclodextrins. Proper fluidity can be maintained, for example, by using coating materials such as lecithin, by maintaining the desired particle size in the case of dispersions, and by using surfactants.
[0292] In another aspect, an enteral pharmaceutical formulation is provided, which includes a disclosed compound and an enteric material; and a pharmaceutically acceptable carrier or excipient thereof. An enteric material refers to a polymer that is substantially insoluble in the acidic environment of the stomach and is primarily soluble in intestinal fluids at a specific pH. The small intestine is a portion of the gastrointestinal tract (intestine) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum. The pH of the duodenum is about 5.5, the pH of the jejunum is about 6.5, and the pH of the terminal ileum is about 7.5.
[0293] Thus, the enteric material is insoluble, for example, until the pH is about 5.0, about 5.2, about 5.4, about 5.6, about 5.8, about 6.0, about 6.2, about 6.4, about 6.6, about 6.8, about 7.0, about 7.2, about 7.4, about 7.6, about 7.8, about 8.0, about 8.2, about 8.4, about 8.6, about 8.8, about 9.0, about 9.2, about 9.4, about 9.6, about 9.8, or about 10.0. Exemplary enteric materials include cellulose acetate phthalate (CAP); hydroxypropyl methylcellulose phthalate (HPMCP); polyvinyl acetate phthalate (PVAP); hydroxypropyl methylcellulose acetate succinate (HPMCAS); cellulose acetate trimellitate; hydroxypropyl methylcellulose succinate; cellulose acetate succinate; cellulose acetate hexahydrophthalate; cellulose propionate phthalate; cellulose acetate maleate; cellulose acetate butyrate; cellulose acetate propionate; copolymers of methyl methacrylic acid and methyl methacrylate; copolymers of methyl acrylate, methyl methacrylate and methacrylic acid; copolymers of methyl vinyl ether and maleic anhydride (Gantrez ES series); ethyl methacrylate-methyl methacrylate-chlorotrimethylammonium ethyl acrylate copolymers; natural resins such as zein, shellac and copal colophorium; and several commercially available enteric dispersion systems (e.g., Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D, Estacryl 30D, Coateric and Aquateric). The solubility of each of the above materials is known or can be easily determined in vitro. The foregoing materials are a list of possible materials, but those skilled in the art who have the benefit of this disclosure will recognize that it is not comprehensive and that there are other enteric materials that meet the objectives described herein.
[0294] Advantageously, kits are provided herein for use by consumers, for example, who need treatment of cancer. Such kits include suitable dosage forms such as those described above; and instructions describing methods of using the dosage forms to mediate, reduce or prevent inflammation. The instructions will guide the consumer or medical personnel to apply the dosage form according to the mode of administration known to those skilled in the art. Such kits can be advantageously packaged and sold in single or multiple kit units. An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are widely used to package pharmaceutical unit dosage forms (tablets, capsules, etc.). Blister packs generally consist of a relatively rigid material sheet covered with a preferably transparent plastic material foil. During the packaging process, a groove is formed in the plastic foil. The groove has the size and shape of the tablet or capsule to be packaged. Next, the tablet or capsule is placed in the groove, and the relatively rigid material sheet is sealed against the plastic foil at the foil face opposite to the direction in which the groove is formed. As a result, the tablet or capsule is sealed in the groove between the plastic foil and the sheet. Preferably, the sheet strength is such that the tablet or capsule can be removed from the blister packing by manually applying pressure on the recess, thereby forming an opening in the sheet at the location of the recess. The tablet or capsule can then be removed through the opening.
[0295] It may be desirable to provide a memory aid on the kit, for example in the form of numbers next to the tablets or capsules, whereby the numbers correspond to the days in the regimen when the tablets or capsules so specified should be taken. Another example of such a memory aid is a calendar printed on a card, such as "week 1, Monday, Tuesday, ... etc.; week 2, Monday, Tuesday, ... etc. ". Other variations of the memory aid are obvious. A "daily dose" may be a single tablet or capsule or several pills or capsules to be taken on a specified date. In addition, a daily dose of the first compound may consist of one tablet or capsule, while a daily dose of the second compound may consist of several tablets or capsules, and vice versa. The memory aid should reflect this. Example
[0296] The compounds described herein can be prepared in a variety of ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described below, it should be understood that, unless otherwise indicated, all proposed reaction conditions including solvent selection, reaction atmosphere, reaction temperature, experimental duration, and treatment procedures can be selected as the condition standard for the reaction. It should be understood by those skilled in the art of organic synthesis that the functional groups present on the various parts of the molecule should be compatible with the proposed reagents and reactions. Substituents that are not compatible with the reaction conditions should be obvious to those skilled in the art, and therefore indicate alternative methods. The starting materials used in the embodiments are commercially available or easily prepared by known materials by standard methods.
[0297] The following abbreviations are used in the present invention and have the following definitions: "ADP" is adenosine diphosphate, "Boc" is tert-butyl carbonate, "CDI" is carbonyldiimidazole, "conc." is concentrated, "Cs2CO3" is cesium carbonate, "CuI" is copper (I) iodide, "DBU" is 1,8-diazabicyclo [5.4.0] undec-7-ene, "DCC" is N,N'-dicyclohexylcarbodiimide, "DCE" is dichloroethane, "DCM" is dichloromethane, "DIEA" is N,N-diisopropylethylamine, "DMA" is N,N-dimethylacetamide, "DMAP" is 4-(dimethylamino)pyridine, "DMF" is N,N-dimethylformamide, "dppf" is 1,1'-bis (diphenylphosphino) ferrocene, and "DMEM" is Dulbecco's Modified Eagle's Medium (Dulbecco's Modified Eagle's Medium). Media), "DMSO" is dimethyl sulfoxide, "DPPA" is diphenylphosphoryl azide, "EDC" is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, "ESI" is electrospray ionization, "Et2O" is diethyl ether, "EtOAc" is ethyl acetate, "EtOH" is ethanol, "GST" is glutathione S-transferase, "h" is hour, "HBTU" is (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, "H2" is hydrogen, "HCl" is hydrochloric acid, "Hex" is hexane, "H2O" is water, "HOBt" is hydroxybenzotriazole, "IC 50" is the half-maximal inhibitory concentration, "K2CO3" is potassium carbonate, "K3PO4" is potassium phosphate, "LiMHDS" is lithium bis(trimethylsilyl)amide, "MeCN" is acetonitrile, "MeOH" is methanol, "Me4tBuXPhos" is di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[1,1'-biphenyl]-2-yl)phosphine, "MgSO4" is magnesium sulfate, "MHz" is megahertz, and "min" is minutes, “MS” is mass spectrometry, “MTBE” is methyl tert-butyl ether, “NADH” is nicotinamide adenine dinucleotide, “NaH” is sodium hydride, “NaHCO3” is sodium bicarbonate, “Na2SO4” is sodium sulfate, “NH4Cl” is ammonium chloride, “NaSMe” is sodium thiomethoxide, “NBS” is N-bromosuccinimide, “NMR” is nuclear magnetic resonance, “PBS” is phosphate-buffered saline, “Pd / C” is palladium / carbon, “Pd2(db a)3" is tris(dibenzylideneacetone)dipalladium(0), "Pd(OAc)2" is palladium(II) acetate, "Pd(PPh3)4" is tetrakis(triphenylphosphine)palladium(0), "prep-HPLC" is preparative high performance liquid chromatography, "PyBOP" is benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, "rt" is room temperature also known as "ambient temperature", which is understood to consist of a range of normal laboratory temperatures in the range of 15°C-25°C, and "s atd." is saturated, "T3P" is n-propanephosphonic anhydride, "TEA" is triethylamine, "TFA" is trifluoroacetic acid, "THF" is tetrahydrofuran, "TMS" is trimethylsilyl, "Tris" is tris(hydroxymethyl)aminomethane, "Xantphos" is 4,5-bis(diphenylphosphino)-9,9-dimethyldibenzoxanthene, "X-Phos" is 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl and "ZnCl2" is zinc chloride.
[0298] General chemical reactions
[0299] The exemplary compounds described herein can be obtained by the general synthetic methods illustrated in the following schemes, intermediate preparations and accompanying examples.
[0300] Synthesis process
[0301] Process 1
[0302]
[0303] Scheme 1 illustrates an exemplary preparation of amines DIi, DI-ii and DI-iii. In the presence of a base (e.g., Cs2CO3 or K2CO3) an amine R which may be aliphatic or heterocyclic is used. 4AI is treated with -H to give compound BI. BI is further treated with commercially available borate / boronic acid / trifluoroborate in the presence of a palladium catalyst, wherein R 2a The intermediate CI can be selectively converted to amine DIi by mild reduction conditions such as zinc or iron metal and ammonium chloride, where R 2b is alkenyl, alkynyl or cycloalkyl. The intermediate CI can be completely reduced to DI-iii by palladium catalyzed hydrogenation. 2a Intermediate BI which is Cl, Br, alkyl, CN or alkoxy can be reduced to DI-ii by mild reducing conditions such as zinc or iron metal with ammonium chloride.
[0304] In Scheme 1, examples of X include N and CH, examples of Y include N, CH and CF, wherein X and Y are not both N, R 2 Examples of include alkyl and cycloalkyl, and R 4 Examples of include N-linked alkyl and N-linked heterocyclyl groups with suitable optional substituents as exemplified in the Intermediate Table below.
[0305] Process 2
[0306]
[0307] Scheme 2 illustrates an exemplary preparation of amines D-II-i, D-II-ii, and D-II-iii. A-II (commercially available starting material) is reacted with an amine R under reductive amination conditions (e.g., sodium cyanoborohydride or sodium triacetoxyborohydride in the presence of a catalytic amount of acetic acid in a polar solvent such as MeOH). 4 B-II is further treated with commercially available borate / boronic acid / trifluoroborate in the presence of a palladium catalyst, wherein R 2a The intermediate C-II can be selectively converted to amine D-II-i by mild reduction conditions such as zinc or iron metal with ammonium chloride, wherein R 2b is alkenyl, alkynyl or cycloalkyl. The intermediate C-II can be completely reduced to D-II-iii by palladium catalyzed hydrogenation. 2a Intermediate B-II which is Cl, Br, alkyl, CN or alkoxy can be reduced to D-II-ii by mild reducing conditions such as zinc or iron metal with ammonium chloride.
[0308] In Scheme 2, examples of X include N and CH, examples of Y include N, CH and CF, wherein X and Y are not both N, R 2 Examples of include alkyl and cycloalkyl, and R 4 Examples of include N-linked alkyl and N-linked heterocyclyl groups with suitable optional substituents as exemplified in the Intermediate Table below.
[0309] Process 3
[0310]
[0311] Scheme 3 illustrates an exemplary preparation of amines D-III-i, D-III-ii, and D-III-iii. A-III-i is reduced with a reducing agent such as DIBAL to give the aldehyde A-III-ii. Another way to prepare A-III-ii is to reduce A-III-i to the corresponding aldehyde followed by mild oxidative conditions such as using MnO2. A-III-ii is reacted with an amine R under reductive amination conditions such as sodium cyanoborohydride or sodium triacetoxyborohydride in the presence of a catalytic amount of acetic acid in a polar solvent such as MeOH. 4 Another way to prepare B-III is to reduce A-III-I to an alcohol, and then convert the alcohol to a sulfonate ester A-III-iii. In the presence of a base such as triethylamine, Hunig's base or cesium carbonate, A-III-iii is reacted with an amine R 4 B-III is further treated with commercially available borate / boronic acid / trifluoroborate in the presence of a palladium catalyst, wherein R 2a The intermediate C-III can be selectively converted to the amine D-III-iii by mild reduction conditions such as zinc or iron metal and ammonium chloride, wherein R 2b is alkenyl, alkynyl or cycloalkyl. The intermediate C-III can be completely reduced to D-III-ii by palladium catalyzed hydrogenation. 2a Intermediate B-III which is Cl, Br, alkyl, CN or alkoxy can be reduced to D-III-i by mild reducing conditions such as zinc or iron metal with ammonium chloride.
[0312] In Scheme 3, examples of X include N and CH, examples of Y include N, CH and CF, wherein X and Y are not both N, examples of R include methyl and ethyl, R 2 Examples of include alkyl and cycloalkyl groups, R 4Examples of include N-bound alkyl and N-bound heterocyclyl with suitable optional substituents as exemplified in the Intermediate Table below, and examples of LG include mesylate and tosylate.
[0313] Process 4
[0314]
[0315] An exemplary preparation of amine D-IV is illustrated in Scheme 4. A-III-i is reacted with various amines in the presence of a catalytic amount of DMAP (if necessary) with an amide coupling agent such as CDI, DCC, EDC, HOBt, HBTU, PyBOP or T3P to afford amide B-IV.
[0316] B-IV is further treated with commercially available borate / boronic acid / trifluoroborate in the presence of a palladium catalyst, wherein R 2a The intermediate C-IV can be selectively converted to the amine D-IV-i by mild reduction conditions such as zinc or iron metal with ammonium chloride, wherein R 2b is alkenyl, alkynyl or cycloalkyl. The intermediate C-IV can be completely reduced to D-IV-iii by palladium catalyzed hydrogenation. 2a Intermediate B-IV which is Cl, Br, alkyl, CN or alkoxy can be reduced to D-IV-ii by mild reducing conditions such as zinc or iron metal with ammonium chloride.
[0317] In Scheme 4, examples of X include N and CH, examples of Y include N, CH and CF, wherein X and Y are not both N, examples of R include methyl and ethyl, R 2 Examples of include alkyl and cycloalkyl, and R 4 Examples include -C(O)-alkyl and -C(O)-heterocyclyl, wherein the alkyl and heterocyclyl moieties are bonded to suitable optional substituents N as exemplified in the Intermediate Table below.
[0318] Process 5
[0319]
[0320] Scheme 5 illustrates an exemplary preparation of amine DV. Reaction of BV with a boronate / boronic acid / trifluoroborate in the presence of a palladium catalyst (Suzuki coupling) affords compound CV. Many boronates / boronic acids / trifluoroborates are commercially available, and those that are not commercially available can be readily prepared from the corresponding carboxylic acids (see Scheme 7). Intermediate C-IV can be converted to amine DV by standard reduction conditions, such as by palladium-catalyzed hydrogenation, or by mild reduction conditions involving zinc metal and ammonium chloride.
[0321] In Scheme 5, embodiments of X include N and CH, embodiments of Y include N, CH and CF, R 2 Examples of include alkyl and cycloalkyl, and R 4 Examples include C-linked heterocyclyl and heteroaryl groups with suitable optional substituents as exemplified in the following table of intermediates.
[0322] Process 6
[0323]
[0324] Scheme 6 illustrates an exemplary preparation of D-VI from C-VI-i, wherein in C-VI-i, R 4 Contains a nitrogen protecting group, such as a Boc group. C-VI-i can be deprotected under acidic conditions to give an amine salt. The salt is further treated with sodium cyanoborohydride or sodium triacetoxyborohydride and an aldehyde or ketone in the presence of a catalytic amount of acetic acid in a polar solvent such as MeOH (reductive amination conditions) to give C-VI. Intermediate C-VI can be converted to aniline D-VI by standard reduction conditions, such as by palladium catalyzed hydrogenation, or by mild reduction conditions involving zinc metal and ammonium chloride.
[0325] In Scheme 6, examples of X include N and CH, examples of Y include N, CH and CF, wherein X and Y are not both N, R 2 Examples of include alkyl and cycloalkyl, and R 4 Examples of include heterocyclyl groups having suitable optional substituents as exemplified in the following table of intermediates.
[0326] Process 7
[0327]
[0328] Scheme 7 illustrates an exemplary preparation of non-commercially available boronic acids / boronic esters T. These compounds can be readily prepared from substituted carboxylic acids. The starting material carboxylic acid can be activated by 2-hydroxyisoindoline-1,3-dione in the presence of a coupling agent such as DCI or Et3N / HATU to afford Q. Intermediate Q is converted to boronate ester T by nickel-catalyzed decarboxylation with a [B2pin2Me]Li complex premixed with methyllithium and B2pin2 (Science, 356, 1045 (2017), JACS, 138, 2174 (2016)).
[0329] In Process 7, embodiments of m include 0, 1 and 2, and R 4 Examples of include alkyl, cycloalkyl and heterocyclyl groups with suitable optional substituents as exemplified in the following table of intermediates.
[0330] Process 8
[0331]
[0332] Scheme 8 illustrates an exemplary preparation of LI-1 and LI-2. Commercially available 2,4-dichloro-5-iodopyrimidine is reacted with TMSCHF2 in the presence of CuI and CsF in a solvent such as NMP or DMF to produce difluoromethylpyrimidine L-II-1 (US20150284341). Difluoromethylpyrimidine L-II-1 can be converted to thiomethyl ethyl ether pyrimidine LI-1 by treatment with diethyl ether containing sodium thiomethoxide and zinc chloride at a temperature below 10°C (WO2012110773). Trifluoromethylpyrimidine LI-2 can be prepared from commercially available 2,4-dichloro-5-(trifluoromethyl)pyrimidine L-II-2 in a similar manner to LI-1.
[0333] Process 9
[0334]
[0335] Scheme 9 illustrates an example in which R 1 Exemplary preparation of sulfonyl pyrimidine L-III (t = 2) which may be cycloalkyl. Commercially available 5-bromo-2-chloro-4-(methylthio)pyrimidine (Suzuki coupling) is treated with commercially available borate / boronic acid / trifluoroborate (see Scheme 7) in the presence of a palladium catalyst to afford sulfonyl pyrimidine L-III (t = 0). The intermediate sulfonyl pyrimidine L-III (t = 0) can be converted to sulfonyl pyrimidine L-III (t = 2) by standard oxidation, for example, by mCPBA.
[0336] Process 10
[0337]
[0338] Scheme 10 illustrates an exemplary preparation of intermediate H (I-XIII) using widely known methods. Commercially available lactam / cyclic carbamate / oxolactam / cyclic urea / diazepanone E is treated with a (Boc)-protected bromo intermediate F in the presence of a base such as sodium hydride or potassium tert-butoxide to afford G. The Boc protecting group of G can be removed upon exposure to an acid such as HCl or TFA.
[0339] In process 10, q can be 0, 1, 2 or 3, r can be 2, 3 or 4, V can be C(R 34 )2. O or NR 6 , where R 6 is an alkyl group, n can be 2, 3 or 4, each R 34 Can be independently H, C1-C6 alkyl, or two R34 Can form a cycloalkyl group together.
[0340] Process 11
[0341]
[0342] In another embodiment for the preparation of H, H-XIV can be prepared from DBU via a one-step process as illustrated in Scheme 11. DBU can be hydrolyzed by methanolic and aqueous potassium hydroxide at ambient temperature to provide H-XIV.
[0343] Process 12
[0344]
[0345] Scheme 12 illustrates an exemplary preparation of key intermediates J and K. Key intermediate J can be prepared from H (free base or acid addition salt) by reaction with thiopyrimidine LI in the presence of an organic base (e.g., triethylamine or DIEA) and optionally heating. Key intermediate K can be prepared in a similar manner from H and L-II or L-III.
[0346] In process 12, q can be 0, 1, 2 or 3, r can be 2, 3 or 4, V can be C(R 34 )2. O or NR 6 , where R 6 is an alkyl group, n can be 2, 3 or 4, each R 34 Can be independently H, C1-C6 alkyl, or two R 34 Can form a cycloalkyl group together.
[0347] Process 13
[0348]
[0349] Scheme 13 illustrates an exemplary preparation of key intermediate M. H treatment with commercially available iodopyridine under Buchwald-Hartwig coupling conditions (Cs2CO3, Xantphos and Pd(OAc)2) is typically performed in an aprotic solvent such as DME, DMF, DMSO or NMP at temperatures ranging from ambient to 140°C to afford key intermediate M.
[0350] In Scheme 13, R 1 can be Br, Cl, an alkyl group or a cycloalkyl group optionally substituted with one or more fluorine atoms, q can be 0, 1, 2 or 3, r can be 2, 3 or 4, V can be C(R 34 )2. O or NR 6 , where R6 is an alkyl group, n can be 2, 3 or 4, each R 34 Can be independently H, C1-C6 alkyl, or two R 34 Can form a cycloalkyl group together.
[0351] Process 14
[0352]
[0353] Scheme 14 illustrates an exemplary preparation of compounds of Formula I from substituted anilines or aminopyridines (DI). The preparation of Formula IA can be achieved from key intermediates K and J. First, the nucleophilic substitution reaction of K with amine D can be typically performed at a temperature ranging from ambient temperature to 150°C in an aprotic solvent, with microwave heating in some embodiments, optionally in the presence of an acid such as 4N HCl in 1,4-dioxane to give Formula IA. Non-commercially available compound DI can be readily prepared from nitrobenzene or nitropyridine (see Schemes 1-6). An alternative general synthesis of Formula IA is performed via a two-step process by first converting J (t=0) to sulfoxide J (t=1, major product) via oxidation using various oxidants such as mCPBA. The sulfoxide is reacted with the amine DI by a nucleophilic substitution reaction typically performed at temperatures ranging from ambient temperature to 150° C. in an aprotic solvent, optionally in the presence of an acid such as 4N HCl in 1,4-dioxane or pTSA. Formula IA containing a nitrogen protecting group such as a Boc group can be deprotected under acidic conditions to give NH at R 4 Formula IA (free amine or acid addition salt) containing free NH on the surface. Formula IA (free base or acid addition salt) is further treated with sodium cyanoborohydride or sodium triacetoxyborohydride and an aldehyde or ketone in the presence of a catalytic amount of a polar solvent (such as MeOH) containing acetic acid (reductive amination conditions) to give R 4 N-Substituted Formula IA. For acylation and sulfonylation, the free amine (or salt) can be treated with commercially available acyl chloride or sulfonyl chloride to afford the N-substituted Formula IA.
[0354] Process 15
[0355]
[0356] Scheme 15 illustrates an exemplary preparation of compounds of Formula IB. The preparation of Formula IB can be achieved by a Buchwald-Hartwig coupling reaction using DI and M. Non-commercially available amines DI can be easily prepared from substituted nitrobenzenes or nitropyridines (see Schemes 1-6). Formula IB containing a nitrogen protecting group such as a Boc group can be deprotected under acidic conditions to give NH at R 4 Formula IB (free amine or acid addition salt) containing free NH on the surface. Formula IB (free base or acid addition salt) is further treated with sodium cyanoborohydride or sodium triacetoxyborohydride and aldehyde or ketone in the presence of a catalytic amount of a polar solvent (such as MeOH) containing acetic acid (reductive amination conditions) to give R 4 N-substituted Formula IB. The free amine (or acid addition salt) can be treated with commercially available acid chloride or sulfonyl chloride in the same manner as in Scheme 14 to provide the N-substituted Formula IB.
[0357] Preparation of intermediates.
[0358] Using the synthetic procedures and methods described herein and methods known to those skilled in the art, the following compounds were made.
[0359] General Method A: Aromatic Nucleophilic Substitution:
[0360] Intermediate BI-8: 1-(3-bromo-4-nitrophenyl)-4-methylpiperazine
[0361]
[0362] A mixture of 2-bromo-4-fluoro-1-nitrobenzene (50 g, 227 mmol) and 1-methylpiperazine (24 g, 250 mmol) in DMF (400 mL) was treated with KCO (63 g, 455 mmol) at RT, and the mixture was stirred at 60° C. for 16 h. The reaction mixture was diluted with ice water (500 mL) and the precipitated solid was filtered. The solid was further triturated with EtO and n-pentane to obtain 1-(3-bromo-4-nitrophenyl)-4-methylpiperazine (58 g, 85% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6): δ7.98 (d, J=9.4Hz, 1H), 7.24 (d, J=2.1Hz, 1H), 7.01 (dd, J= 2.2 and 9.4Hz, 1H), 3.42 (m, 4H), 2.40 (m, 4H), 2.19 (s, 3H); LC-MS (ESI) m / z: 299.0 (M+H) + ).
[0363] General method B: Removal of protecting groups and reductive amination:
[0364] Intermediate BI-24: 3-(3-bromo-4-nitrophenyl)-8-methyl-3,8-diazabicyclo[3.2.1]octane
[0365]
[0366] A solution of tert-butyl 3-(3-bromo-4-nitrophenyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (BI-14, 2.57 g, 6.2 mol) in MeOH (30 mL) was treated with 4N HCl in 1,4-dioxane (16 mL, 62 mmol) and the reaction mixture was stirred at rt for 16 hours. The reaction mixture was concentrated to dryness in vacuo to give 3-(3-bromo-4-nitrophenyl)-3,8-diazabicyclo[3.2.1]octane hydrochloride (2.17 g, 100% yield) as a white solid. The material was carried forward to the next step without further purification. A suspension of 3-(3-bromo-4-nitrophenyl)-3,8-diazabicyclo[3.2.1]octane hydrochloride (1.92 g, 5.5 mmol) in DCE (25 mL) was treated with DIEA (2.9 mL, 17 mmol) and formaldehyde (1.2 mL, 17 mmol). The yellow suspension became a clear orange solution. The reaction mixture was stirred at rt for 10 minutes, and then acetic acid (0.63 mL, 11 mmol) was added. The orange solution became a yellow suspension, which was stirred for 20 minutes. Sodium triacetoxyborohydride (2.33 g, 11 mmol) was added, and the reaction mixture was stirred at rt for 4 hours. The reaction mixture was diluted with aqueous NaHCO3 (50 mL), and the solution was extracted with DCM (3×50 mL). The combined organics were dried over anhydrous Na2SO4, filtered and concentrated to give a brown solid. The brown solid was purified by silica gel column chromatography (0% to 15% MeOH / DCM) to give 3-(3-bromo-4-nitrophenyl)-8-methyl-3,8-diazabicyclo[3.2.1]octane (1.71 g, 95% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6): δ7.98 (d, J = 9.4Hz, 1H), 7.10 (d, J = 2.7Hz, 1H), 6.89 (dd, J = 9.5 and 2.7Hz, 1H), 3.54 (d, J = 11.6Hz, 2H),3.22(brs,2H),2.99-3.04(m,2H),2.22(s,3H),1.92-1.95(m,2H),1.52-1.56(m,2H); LC-MS(ESI)m / z:326.0(M+H) + ).
[0367] General Method C: Alkylation:
[0368] Intermediate BI-23: 1-(2-fluoroethyl)-4-(3-methyl-4-nitrophenyl)piperazine
[0369]
[0370] A mixture of 1-(3-methyl-4-nitrophenyl)piperazine hydrochloride (Boc-deprotected product of BI-3, 1.5 g, 0.58 mmol) and KCO (4.0 g, 2.9 mmol) in 1,4-dioxane (20 mL) was treated with 1-fluoro-2-iodoethane (2.0 mL, 2.6 mmol) [Note: material described as prone to instability - some solid present in orange liquid], capped tightly and heated to 100 °C for 24 h. The reaction mixture was cooled to rt and the solid (KCO) was removed by filtration, rinsed with DCM, and the filtrate was concentrated to dryness to give 1-(2-fluoroethyl)-4-(3-methyl-4-nitrophenyl)piperazine (1.52 g, 98% yield) as a yellow oil which solidified to an amber solid upon standing. 1 H NMR (400MHz, DMSO-d6): δ7.97(d,J=9.6Hz,1H),6.87-6.89(m,2H),4.61(t,J=4.9Hz,1H),4.52(t,J=4.9Hz,1 H),3.41(m,4H),2.69(t,J=4.9Hz,1H),2.63(t,J=4.9Hz,1H),2.54-2.56(m,7H); LC-MS(ESI)m / z:268.2(M+H) + ).
[0371] Using General Procedures AC above, the intermediates in Table A below were prepared.
[0372] Table A
[0373]
[0374]
[0375]
[0376]
[0377]
[0378]
[0379]
[0380] Intermediate BI-33: 1-(3-bromo-4-nitrophenyl)-4-methylpiperazin-2-one.
[0381]
[0382] A mixture of tert-butyl (2-aminoethyl)(methyl)carbamate (4.3 g, 24 mmol) and potassium carbonate (3.8 g, 27 mmol) in DMF (50 mL) was treated with 4-fluoro-2-bromo-1-nitrobenzene (5 g, 22 mmol) at rt under N2 atmosphere and the mixture was stirred at 90°C for 16 hours. The reaction mixture was diluted with water (200 mL) and the solution was extracted with EtOAc (2 x 100 mL), the combined organics were dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography (2% MeOH / DCM, 10 CV's) to give tert-butyl (2-((3-bromo-4-nitrophenyl)amino)ethyl)(methyl)carbamate (5.6 g, 66% yield) as a yellow liquid. 1 H NMR (400MHz, DMSO-d6): δ7.98(d,J=9.0Hz,1H),6.77(S,1H),6.46(d,J=9.0Hz,1H),3. 54(s,2H),3.31(t,J=6.0Hz,2H),2.90(s,3H),1.47(s,9H); LC-MS(ESI)m / z:374.1(M+H + ).
[0383] A mixture of tert-butyl (2-((3-bromo-4-nitrophenyl)amino)ethyl)(methyl)carbamate (5.6 g, 15 mmol) and TEA (7.6 g, 75 mmol) in DCM (100 mL) was treated with chloroacetyl chloride (5.1 g, 45 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at rt for 16 h. The reaction mixture was diluted with water (100 mL) and the solution was extracted with EtOAc (2 x 100 mL). The combined organics were evaporated under reduced pressure and the crude product was purified by silica gel column chromatography (2% MeOH / DCM, 10 CV's) to give tert-butyl (2-(N-(3-bromo-4-nitrophenyl)-2-chloroacetylamino)ethyl)(methyl)carbamate (5.6 g, 66% yield) as a yellow liquid. 1H NMR (400MHz, DMSO-d6): δ8.12(d,J=8.6Hz,1H),7.97(s,1H),6.66(d,J=7.4Hz,1H),4.24 (m,2H),3.82(s,2H),3.18(s,2H),2.70(s,3H),1.41(s,9H); LC-MS(ESI)m / z:374.1(M+H + ).
[0384] A solution of N-(3-bromo-4-nitrophenyl)-2-chloro-N-(2-(methylamino)ethyl)acetamide hydrochloride (5.6 g, 12 mmol) in dioxane (100 mL) was treated with 4N HCl in 1,4-dioxane (100 mL) at 0°C under N2 atmosphere, and the reaction mixture was stirred at rt for 16 hours. The reaction mixture was evaporated under reduced pressure, and the crude product was purified by crystallization in Et2O (100 mL) to obtain N-(3-bromo-4-nitrophenyl)-2-chloro-N-(2-(methylamino)ethyl)acetamide hydrochloride (4.79 g, 99% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6): δ8.75 (brs, 2H), 8.16 (m, 2H), 7.83 (d, J = 7.8Hz, 1H), 4.20 (s, 2H),3.98(t,2H),3.20(s,2H),2.56(s,3H),1.41(s,9H); LC-MS(ESI)m / z:374.1(M+H + ).
[0385] A solution of N-(3-bromo-4-nitrophenyl)-2-chloro-N-(2-(methylamino)ethyl)acetamide hydrochloride (5.0 g, 12 mmol) in DMF (50 mL) was added to 60% mineral oil (1.1 g, 25 mmol) containing NaH at 0°C under N2 atmosphere, and the reaction mixture was stirred at rt for 2 hours. The reaction mixture was diluted with water (100 mL) and the solution was extracted with EtOAc (2 x 50 mL), the combined organics were evaporated under reduced pressure, and the crude product was purified by silica gel column chromatography (2% MeOH / DCM, 10 CV's) to give 1-(3-bromo-4-nitrophenyl)-4-methylpiperazin-2-one (3.1 g, 76% yield) as a yellow solid. 1HNMR (400MHz, DMSO-d6): δ8.0 (d, J = 9.4Hz, 1H), 7.24 (d, J = 2.3Hz, 1H), 6.99 (dd, J = 2.3 and 9.3Hz, 1H) ,4.0(s,2H),3.72(t,J=5.4Hz,2H),3.45(t,J=5.4Hz,2H),2.90(s,3H); LC-MS(ESI)m / z:314.2(M+H + ).
[0386] Intermediate BI-34: 1-(3-(methoxymethyl)-4-nitrophenyl)-4-methylpiperazine:
[0387]
[0388] A solution of (5-(4-methylpiperazin-1-yl)-2-nitrophenyl)methanol (1.0 g, 4.0 mmol) in DMF (30 mL) was cooled to 0 °C. Sodium hydride (0.80 g, 60% in mineral) was added portionwise, and the mixture was stirred under the same conditions. Iodomethane (1.7 g, 12 mmol) was added at 0 °C, and the mixture was slowly warmed to rt and stirred for 2 hours. The reaction was diluted with EtOAc and carefully quenched with ice water. The mixture was extracted with EtOAc (3 x 30 mL), and the combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography (hexane / EtOAc), 1-(3-(methoxymethyl)-4-nitrophenyl)-4-methylpiperazine (0.76 g, 72% yield). 1 H NMR (400MHz, DMSO-d6): δ8.03(m,1H),7.08(s,1H),6.96(m,1H),4.76(s,2H),3.4 5(brs,4H),3.40(s,3H),2.42(brs,4H),2.22(s,3H); LC-MS(ESI)m / z:266.2(M+H + ).
[0389] General method D: Suzuki coupling reaction:
[0390] Intermediate CV-4: 1-methyl-4-(3-methyl-4-nitrophenyl)-1H-imidazole:
[0391]
[0392] A suspension of 4,4,5,5-tetramethyl-2-(3-methyl-4-nitrophenyl)-1,3,2-dioxaborolane (0.80 g, 3.0 mmol) and 4-bromo-1-methyl-1H-imidazole (0.49 g, 3.0 mmol) in a mixture of 1,4-dioxane (12 mL) and water (0.5 mL) was treated with potassium carbonate (1.26 g, 9.1 mmol) and the suspension was allowed to stir. The reaction mixture was degassed by bubbling argon for two minutes and treated with Pd(dppf)Cl2.DCM adduct (0.50 g, 0.61 mmol). The resulting reaction mixture was heated at 100°C for 16 hours. The reaction was diluted with water and extracted with DCM (4 x 25 mL). The organics were combined and dried over anhydrous Na2SO4, filtered and concentrated to dryness in vacuo to give a black oil. The black oil was purified using silica gel (0% to 15% MeOH / DCM, 15 CV's) to afford 1-methyl-4-(3-methyl-4-nitrophenyl)-1H-imidazole (0.31 g, 47% yield). 1 H NMR (400MHz, DMSO-d6): δ8.02(d,J=8.6Hz,1H),7.84(d,J=7.7Hz,2H),7.77(d,J =8.6Hz,1H),7.72(s,1H),3.70(s,3H),2.57(s,3H); LC-MS(ESI)m / z:218.2(M+H + ).
[0393] Using General Procedure D above, the intermediates in Table B below were prepared.
[0394] Table B
[0395]
[0396]
[0397] General Method E: Suzuki Coupling Reaction
[0398] Intermediate CI-1: 1-(3-cyclopropyl-4-nitrophenyl)-4-methylpiperazine
[0399]
[0400] A mixture of 1-(3-bromo-4-nitrophenyl)-4-methylpiperazine (BI-8, 20 g, 67 mmol) and cyclopropylboronic acid (8.6 g, 100 mmol) in toluene:H2O (9:1) (200 mL) was treated with K3PO4 (43 g, 200 mmol), and the reaction mixture was flushed with nitrogen for 20 minutes. Tricyclohexylphosphine (3.7 g, 13 mmol) and Pd(OAc)2 (2.2 g, 10 mmol) were added to the reaction mixture, and then the reaction mixture was stirred at 100°C for 5 hours. The reaction mixture was diluted with water (100 mL) and the solution was extracted with EtOAc (3×200 mL). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography (0% to 80% EtOAc / hexanes, 15 CV's) to obtain 1-(3-cyclopropyl-4-nitrophenyl)-4-methylpiperazine (12 g, 69% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6): δ7.89 (d, J=9.3Hz, 1H), 6.85 (dd, J=2.4 and 9.4Hz 1H),6.55(s,1H),3.36(m,4H),2.45(m,1H),2.40(m,4H),2.20(s,3H),0.94(m,2H),0.75(m,2H); LC-MS(ESI)m / z:261.3(M+H) + ).
[0401] General Method F: Suzuki Coupling Reaction
[0402] Intermediate CI-12: 1-methyl-4-(4-nitro-3-vinylphenyl)piperazine
[0403]
[0404] A mixture of 1-(3-bromo-4-nitrophenyl)-4-methylpiperazine (BI-8, 30 g, 100 mmol) and potassium trifluoroethylene borate (20 g, 150 mmol) in DMSO (210 mL) was treated with KCO (42 g, 301 mmol) at rt, and the reaction mixture was flushed with nitrogen for 15 minutes. PdCl(dppf) (3.7 g, 5.0 mmol) was added to the reaction mixture and the reaction mixture was stirred at 80 °C for 3 hours. The reaction mixture was diluted with cold water (300 mL) and the solution was extracted with EtOAc (3 x 250 mL). The combined organic extracts were washed with brine (200 mL), dried over anhydrous NaSO, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0% to 80% EtOAc / hexanes, 10 CV's) to obtain 1-methyl-4-(4-nitro-3-vinylphenyl)piperazine (20 g, 81% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6): δ7.96(d,J=9.2Hz,1H),7.21(m,1H),6.98(m,2H),5.77(t,J=17.2Hz,1H),5.41( d,J=11.2Hz,1H),3.44(t,J=4.8Hz,4H),2.42(t,J=4.8Hz,4H),2.21(s,3H); LC-MS(ESI)m / z:247.3(M+H + ).
[0405] The intermediates in Table C below were prepared using General Procedure E or General Procedure F for the Suzuki reaction.
[0406] Table C
[0407]
[0408]
[0409]
[0410]
[0411]
[0412]
[0413]
[0414] General Method G: Reduction
[0415] Intermediate DI-1: 2-cyclopropyl-4-(4-methylpiperazin-1-yl)aniline
[0416]
[0417] A solution of 1-(3-cyclopropyl-4-nitrophenyl)-4-methylpiperazine (CI-1, 12 g, 46 mmol) in MeOH (60 mL) at 0 ° C was treated with NH4Cl (73 g, 14 mmol), and the reaction mixture was stirred at 0 ° C for 10 minutes. Zinc powder (30 g, 459 mmol) was slowly added to the reaction mixture (internal temperature was raised to 20 ° C) under an ice-water bath. After stirring for 15 minutes, the reaction mixture was warmed to rt and stirred vigorously at rt for 16 hours. The mixture was filtered through a celite pad and washed with THF (500 mL). The filtrate was concentrated under reduced pressure to give 2-cyclopropyl-4-(4-methylpiperazine-1-yl)aniline (10 g, 95%) as a dark brown viscous solid. 1 H NMR (400MHz, DMSO-d6): δ6.52(m,2H),6.43(d,J=2.0Hz,1H),4.52(brs,2H),2.88(m,4H),2. 42(m,4H),2.20(s,3H),1.65(m,1H),0.813(m,2H),0.471(m,2H); LC-MS(ESI)m / z:213.2(M+H + ).
[0418] General Method H: Reduction
[0419] Intermediate DI-11: 2-ethyl-4-(4-methylpiperazin-1-yl)aniline
[0420]
[0421] A solution of 1-methyl-4-(4-nitro-3-vinylphenyl)piperazine (CI-12, 20 g, 81 mmol) in EtOAc (200 mL) was treated with Pd / C (20 g, 10% w / w, 50% humidity) under nitrogen atmosphere, and then the mixture was stirred at rt under hydrogen balloon pressure for 3 hours. After general work-up, 2-ethyl-4-(4-methylpiperazin-1-yl)aniline (16 g, 90% yield) was obtained as a brown sticky solid. 1 H NMR (400MHz, DMSO-d6): δ6.61(s,1H),6.52(m,2H),4.25(brs,2H),2.89(t,J=4.4H z,4H),2.41(m,6H),2.19(s,3H),1.09(t,J=7.6Hz,3H); LC-MS(ESI)m / z:219.3(M+H + ).
[0422] Using General Methods G or H for the preparation of DI-1 or DI-11, the intermediates in Table D below were prepared.
[0423] Table D
[0424]
[0425]
[0426]
[0427]
[0428]
[0429]
[0430]
[0431]
[0432]
[0433]
[0434] Intermediate DV-6: 2-ethyl-4-(1-methylpyrrolidin-3-yl)aniline
[0435]
[0436] A solution of tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (0.25 g, 0.85 mmol), 4-bromo-2-ethylaniline (0.121 g, 0.60 mmol) in a mixture of 1,4-dioxane (5 mL) and water (1 mL) was treated with K2CO3 (0.251 g, 1.8 mmol). The mixture was degassed with Ar for 2 min, and then bis(triphenylphosphine)palladium(II)dichloride (0.042 g, 0.06 mmol) was added. The reaction mixture was heated at 95 °C overnight under microwave. The reaction mixture was cooled to rt and the mixture was extracted with EtOAc (2×). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (0% to 60% EtOAc / hexanes, 15CV) to give tert-butyl 3-(4-amino-3-ethylphenyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (0.12 g, 70% yield), which was carried forward to the next step without further purification. LC-MS m / z: 289.2 (M+H + ).
[0437] A solution of tert-butyl 3-(4-amino-3-ethylphenyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (0.12 g, 0.42 mmol) in MeOH (20 mL) was treated with Pd—C (0.040 g, 0.0424 mmol). The reaction mixture was kept under a balloon overnight. The mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure to give tert-butyl 3-(4-amino-3-ethylphenyl)pyrrolidine-1-carboxylate (0.12 g, 97% yield) as a colorless viscous oil. 1 H NMR(400MHz,DMSO-d6):d 6.81(s,1H),6.80(m,1H),6.53(d,J=8.0Hz,1H),4.68(s,2H),3.57(m,1H),3.41(m,1H),3.11-3.29(m,2H), 3.04(m,1H),2.40(q,J=7.5Hz,2H),2.08(brm,1H),1.75(brm,1H),1.39(s,9H),1.09(t,J=7.5Hz,3H); LC-MS m / z:313.2(M+H+Na + ).
[0438] A solution of tert-butyl 3-(4-amino-3-ethylphenyl)pyrrolidine-1-carboxylate (0.12 g, 0.40 mmol) in a biphasic mixture of EtOAc (25 mL) and saturated NaHCO3(aq) (25 mL) was treated with benzyl chloroformate (0.086 mL, 0.60 mmol). The mixture was stirred overnight at rt. The mixture was partitioned between EtOAc and saturated NaHCO3, and EtOAc (2×25 mL) was extracted. The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 3-(4-(((benzyloxy)carbonyl)amino)-3-ethylphenyl)pyrrolidine-1-carboxylate (0.18 g, 100% yield), which was carried forward to the next step without further purification. LC-MS m / z: 447.2 (M+H+Na + ).
[0439] A solution of tert-butyl 3-(4-(((benzyloxy)carbonyl)amino)-3-ethylphenyl)pyrrolidine-1-carboxylate (0.18 g, 0.44 mmol) in DCM (3 mL) was treated with TFA (2 mL). The mixture was stirred at rt for 1 hour. The solvent was removed to give a crude TFA salt. The crude product was suspended in DCM and TEA (1 mL) was added. The solvent was removed under reduced pressure and dried in vacuo. The resulting mixture was suspended in DCM and AcOH (3 drops). Formaldehyde (5 drops) was added and the mixture was stirred at rt for 1 hour. Sodium triacetoxyborohydride (0.37 g, 1.7 mmol) was added and the mixture was stirred at rt overnight.
[0440] The mixture was partitioned between EtOAc and saturated NaHCO3 and stirred for 1 hour. The mixture was extracted with DCM (2×25 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give benzyl (2-ethyl-4-(1-methylpyrrolidin-3-yl)phenyl)carbamate (0.14 g, 94% yield), which was carried forward to the next step without further purification. LC-MS m / z: 339.2 (M+H + ).
[0441] A solution of benzyl (2-ethyl-4-(1-methylpyrrolidin-3-yl)phenyl)carbamate (0.14 g, 0.41 mmol) in EtOAc (20 mL) was flushed with Ar. Palladium on carbon (0.022 g, 0.02 mmol) was added and the mixture was hydrogenated under a balloon at rt overnight. The mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure to give (2-ethyl-4-(1-methylpyrrolidin-3-yl)aniline (0.10 g, 119% yield), which was carried forward to the next step without further purification. LC-MS m / z: 205.2 (M+H +).
[0442] General method for alkylation of Z lactam and deprotection of Boc group:
[0443] Intermediate H-VII-1.
[0444]
[0445] A solution of 1,4-oxazacycloheptane-5-one (10 g, 87 mmol) in anhydrous THF (400 mL) at 0 ° C was treated with sodium hydride (3.0 g, 130 mmol) in batches under a nitrogen atmosphere. The reaction mixture was stirred at 0 ° C for 15 minutes, followed by the addition of tert-butyl (3-bromopropyl)carbamate (21 g, 87 mmol). The solution was continued to be stirred from 0 ° C to rt for 16 hours. The reaction mixture was quenched with saturated NH4Cl solution (200 mL), and the solution was then extracted with EtOAc (2 × 150 mL). The combined organic extracts were washed with brine (150 mL), dried over anhydrous Na2SO4, and filtered under reduced pressure. The crude product was purified by silica gel column chromatography (40% to 50% EtOAc / hexanes, 15 CV's) to afford tert-butyl (3-(5-oxo-1,4-oxazepan-4-yl)propyl carbamate (12 g, 50% yield) as a yellow liquid. The product was dissolved in DCM (50 mL) and treated with 4N HCl in 1,4-dioxane (4 equiv). The mixture was stirred at rt for 3 h and concentrated, dried under high vacuum to afford 4-(3-aminopropyl)-1,4-oxazepan-5-one HCl salt (100% yield). 1 H NMR (400MHz, DMSO-d6): δ8.09(brs,3H),3.62(m,4H),3.49(m,2H),3.35(t,J=6.8 Hz,2H),2.73(m,2H),2.62(t,J=4.8Hz,2H),1.78(m,2H); MS(ESI)m / z:173.2(M+H + ).
[0446] Using the general method for the preparation of H-VII-1, intermediates H-II-1 to H-VI-1 in Table E below were prepared.
[0447] Table E
[0448]
[0449]
[0450] Intermediate H-XIV: 1-(3-aminopropyl)azepan-2-one.
[0451]
[0452] A suspension of DBU (22 g, 145 mmol) in MeOH:HO (1:1) (130 mL) was treated with KOH (12 g, 217 mmol) at 0 °C under N2 atmosphere, and the reaction mixture was stirred at rt for 16 hours. The reaction mixture was evaporated under reduced pressure, and the residue was diluted with water (200 mL). The solution was extracted with 10% MeOH / DCM (3×250 mL), and the combined organic extracts were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 1-(3-aminopropyl)azepan-2-one (21 g, 85% yield) as a liquid oil. 1 H NMR (400MHz, CDCl3): δ3.45(t,J=3.5Hz,2H),3.31(t,J=4.4Hz,2H),2.68(t,J=6.5H z,2H),2.51(t,J=5.8Hz,2H),1.70(m,2H),1.65(m,8H); LC-MS(ESI)m / z:171.4(M+H + ).
[0453] Intermediate L-III-1: 2-chloro-5-cyclopropyl-4-(methylsulfonyl)pyrimidine.
[0454]
[0455] (A) A suspension of 5-bromo-2-chloro-4-(methylthio)pyrimidine (25.0 g, 105 mmol) and cyclopropylboronic acid (13.7 g, 158 mmol) in toluene H2O (9:1) (650 mL) was treated with the addition of K3PO4 (66.7 g, 315 mmol). The reaction mixture was flushed with nitrogen for 20 min, and then tricyclohexylphosphine (5.9 g, 21 mmol) and Pd(OAc)2 (2.35 g, 10.50 mmol) were added. The reaction mixture was stirred at 90 °C for 16 h. The reaction mixture was diluted with water (200 mL) and extracted with EtOAc (3×300 mL). The combined organic extracts were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0% to 10% EtOAc / hexanes) to obtain 2-chloro-5-cyclopropyl-4-(methylthio)pyrimidine (14.0 g, 66% yield) as a yellow oil. 1 H NMR (400MHz, DMSO-d6): δ7.92 (s, 1H), 2.58 (s, 3H), 1.67 (m, 1H), 1.03 (m, 2H), 0.67 (m, 2H); LC-MS (ESI) m / z: 201.0 (M+H)+ ).
[0456] (B) A solution of 2-chloro-5-cyclopropyl-4-(methylthio)pyrimidine (4.0 g, 20 mmol) in DCM (60 mL) at 0 ° C was treated with m-CPBA (4.8 g, 28 mmol). The reaction mixture was warmed to rt and stirred for 3 hours. The reaction mixture was washed with saturated NaHCO3 aqueous solution (2×40 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain 2-chloro-5-cyclopropyl-4-(methylsulfonyl)pyrimidine (3.6 g, 86% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6): δ8.57(s,1H),2.89(s,3H),2.16(m,1H),1.16(m,2H),0.93(m,2H); LC-MS(ESI)m / z:217.0(M+H) + ).
[0457] Intermediate LI-2: 4-chloro-2-(methylthio)-5-(trifluoromethyl)pyrimidine.
[0458]
[0459] A solution of 2,4-dichloro-5-(trifluoromethyl)pyrimidine (100 g, 0.46 mol) in diethyl ether (2 L) was treated dropwise with ZnCl2 (1.0 N in ether) (555 mL, 0.56 mol) at 0 ° C, and the reaction mixture was stirred for 2 hours. Sodium thiomethoxide (49 g, 0.94 mol) was added at 0 ° C, and the reaction mixture was warmed to rt and stirred for 48 hours. The reaction mixture was quenched with 2N HCl under an ice-water bath, and the solution was then extracted with Et2O (3×500 mL). The combined organic extracts were washed with water (500 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure at 35 ° C to obtain 4-chloro-2-(methylthio)-5-(trifluoromethyl)pyrimidine (100 g, yield 95%) as a colorless liquid. 1 H NMR (400MHz, DMSO-d6): δ9.01 (s 1H), 2.62 (s 3H).
[0460] General method for substitution reactions:
[0461] Intermediate J-7: 4-(3-((2-(methylthio)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one
[0462]
[0463] A solution of 4-(3-aminopropyl)1,4-oxazepan-5-one hydrochloride (H-VII-1, 3.0 g, 17.4 mmol) in DMF (60 mL) was treated with DIEA (15.5 ml, 87.2 mmol) at 0 ° C and stirred for 15 min. Subsequently, 4-chloro-2-(methylthio)-5-(trifluoromethyl)pyrimidine (LI-2, 6.0 g, 26.2 mmol) was added and stirring was continued from 0 ° C to rt for 16 hours. The reaction mixture was quenched with ice water (120 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (40% to 50% EtOAc / hexanes, 15 CV's) to obtain 4-(3-((2-(methylthio)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one (3.0 g, 47% yield) as a yellow liquid. 1 H NMR (400MHz, DMSO-d6): δ8.25(s,1H),7.52(bs,1H),3.64(m,4H),3.47(m,2H),3.42(m,2H) ,3.32(m,2H),2.63(t,J=4.8Hz,2H),2.47(s,3H),1.68(m,2H); LC-MS(ESI)m / z:365.3(M+H + ).
[0464] Using the general procedure for the preparation of intermediate J-7, the intermediates in Table F below were prepared.
[0465] Table F
[0466]
[0467]
[0468]
[0469] General method for Pd coupling reactions:
[0470] Intermediate M-1: 4-(3-((2-(methylthio)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one
[0471]
[0472] A solution of 1-(3-aminopropyl)piperidin-2-one hydrochloride (H-III-1, 9.0 g, 29.3 mmol) and 2-chloro-4-iodo-5-(trifluoromethyl)pyridine (6.19 g, 32.2 mmol) in toluene (180 mL) was treated with cesium carbonate (23.9 g, 73.2 mmol). The mixture was flushed with Ar for 15 min. Subsequently, PdCl2(dppf) was added . DCM (2.39 g, 2.93 mmol), and the mixture was rinsed with Ar for another 5 minutes. The sealed tube was closed and heated conventionally at 90 ° C in a preheated oil bath for 16 hours. The reaction mixture was cooled to rt and poured into water (100 mL). The solution was extracted with EtOAc (3 × 100 mL). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (40% to 45% EtOAc / hexane, 12CV's) to obtain 1- (3- ((2- chloro-5- (trifluoromethyl) pyridin-4-yl) amino) propyl) piperidine-2-one (2.6 g, yield 26%) as a brown solid. 1 H NMR (400MHz, DMSO-d6): δ8.18(s,1H),6.98(t,J=6Hz,1H),6.88(s,1H),3.29(m, 2H),3.15(m,4H),2.22(t,J=6.4Hz,2H),1.67(m,6H); LC-MS(ESI)m / z:336.1(M+H + ).
[0473] Using the general procedure for the preparation of intermediate M-1, the intermediates in Table G below were prepared.
[0474] Table G
[0475]
[0476] General procedure for oxidation to sulfinyl intermediates:
[0477] Intermediate J-14: 4-(3-((2-(methylsulfinyl)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one
[0478]
[0479] A solution of 4-(3-((2-(methylthio)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one (J-7, 3.0 g, 8.2 mmol) in DCM (60 mL), m-CPBA (2.0 g, 11.5 mmol) was added at 0° C. and stirred from 0° C. to room temperature for 3 hours. The reaction mixture was washed with saturated aqueous sodium bicarbonate solution (2×90 mL). The organic layer was dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure to give a mixture of 4-(3-((2-(methylsulfinyl)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one and 4-(3-((2-(methylsulfonyl)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one (3.0 g, 95%, 9:1) as a light yellow semisolid. 1 HNMR(400MHz,DMSO-d6): δ8.59(s,1H),7.94(brs,1H),3.60(m,4H),3.45(m,4H) ,3.36(m,2H),2.88(s,3H),2.63(m,2H),1.70(m,2H); LC-MS(ESI)m / z:381.3(M+H + ).
[0480] Using the general procedure for the preparation of intermediate J-14, the intermediates in Table H below were prepared.
[0481] Table H
[0482]
[0483]
[0484] Exemplary compounds: Using the methods described above, the following compounds of Formula IA and Formula IB were prepared. The compounds of Formula IA and Formula IB are shown in Table I below. Exemplary methods for preparing the compounds are also provided below.
[0485] General Method I: Substitution Reaction
[0486] Example 23: 1-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one
[0487]
[0488] A solution of 1-(3-((5-bromo-2-chloropyrimidin-4-yl)amino)propyl)piperidin-2-one (K-10, 4.0 g, 11.6 mmol) in 2-butanol (80 mL) at rt was treated with 2-ethyl-4-(4-methylpiperazin-1-yl)aniline (DI-11, 2.53 g, 11.6 mmol). The reaction mixture was treated with 4N HCl in 1,4-dioxane (3.5 mL, 13.9 mmol) and stirred at 95 °C for 72 hours. The reaction mixture was cooled to rt and then basified with saturated aqueous NaHCO3 solution. The solution was extracted with DCM (3×50 mL), and the combined organics were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (4% to 5% MeOH / DCM, 10 CV's). The product was dissolved in DCM (200 mL) and QuadraSil-MP resin (w / w) was added to remove residual palladium. The solution was stirred for 4 hours and filtered. The filtrate was evaporated to give 1-(3-((5-bromo-2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-one (1.70 g, 28% yield) as an off-white solid. 1 H NMR (400MHz, DMSO-d6): δ8.09(s,1H),7.81(s,1H),7.13(d,J=8.5Hz,1H),6.80(m,1H),6.74(m,1H),6.71(m,1H),3.21(m,4H),3 .14(m,2H),3.07(m,5H),2.43(m,5H),2.21(s,5H),1.67(s,4H),1.61(m,2H),1.05(t,J=7.4Hz,3H); LC-MS(ESI)m / z:530.3(M+H) + ).
[0489] General Method J: Substitution Reactions
[0490] tert-Butyl 4-(4-((4-((3-(2-oxopiperidin-1-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)-1,4-diazepane-1-carboxylic acid
[0491]
[0492] A solution of tert-butyl 4-(4-aminophenyl)-1,4-diazepane-1-carboxylate (DI-12, 0.21 g, 0.57 mmol) and 1-(3-((2-(methylsulfinyl)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one (J-9, 0.17 g, 0.57 mmol) in DMF (3.0 mL) was sealed and heated at 90 °C for 12 h. The mixture was concentrated and the crude product was purified by silica gel column chromatography (0% to 4% MeOH / DCM, 12 CV's) to give tert-butyl 4-(4-((4-((3-(2-oxopiperidin-1-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)-1,4-diazepane-1-carboxylate (0.20 g, 60% yield). LC-MS (ESI) m / z: 592.4 (M+H + ).
[0493] General Method K:R 4 Partial deprotection of Boc groups
[0494] Example 9: 1-(3-((2-((4-(1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one
[0495]
[0496] A solution of tert-butyl 4-(4-((4-((3-(2-oxopiperidin-1-yl)propyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)-1,4-diazepane-1-carboxylate (0.20 g, 0.34 mmol) in DCM (3 mL) was treated with 4N HCl in 1,4-dioxane (1.0 mL). The mixture was stirred at rt for 2 h. The solution was concentrated and the residue was dissolved in water (1.0 mL) and acetonitrile (1 mL), frozen and lyophilized to give 1-(3-((2-((4-(1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one (0.12 g, 67% yield). 1H NMR (400MHz, DMSO-d6): δ9.23(brs,1H),8.27(s,1H,FA),8.08(s,1H),7.47(d,J=8.5Hz,2H ),7.06(s,1H),6.67(d,J=8.5Hz,2H),3.51(t,J=5.0Hz,2H),3.47(t,J=6.2Hz,3H),3.34-3 .37(m,3H),3.30(t,J=6.9Hz,3H),3.20(s,3H),2.98(t,J=4.9Hz,2H),2.80(t,J=5.6Hz,2H ),2.21(t,J=6.0Hz,2H),1.87-1.90(m,2H),1.69-1.75(m,7H); LC-MS(ESI)m / z:492.4(M+H) + ).
[0497] General Method L:R 4 Partial reductive alkylation
[0498] Example 10: 1-(3-((2-((4-(4-ethyl-1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one
[0499]
[0500] A solution of 1-(3-((2-((4-(1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one (9, 0.10 g, 0.20 mmol) in methanol (0.5 mL) was treated with acetaldehyde (0.1 mL 1.8 mmol) and acetic acid (2 drops). Sodium cyanoborohydride (0.026 g, 0.41 mmol) was added and the mixture was stirred at rt for 6 hours. The solution was treated with brine and then extracted with EtOAc (3×15 mL). The combined organics were dried over anhydrous Na 2 SO 4 , filtered and concentrated. The crude product was purified by reverse phase column chromatography (0% to 20% CH3CN / H2O (0.1% FA), 15CV's) to afford 1-(3-((2-((4-(4-ethyl-1,4-diazepan-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one (56 mg, 49% yield). 1H NMR (400MHz, DMSO-d6): δ9.21(brs,1H),8.17(s,1H,FA),8.08(s,1H),7.45(d,J=8.3Hz, 2H),7.05(s,1H),6.63(d,J=8.7Hz,2H),3.47(t,J=4.9Hz,3H),3.36-3.42(m,5H),3.30(t ,J=6.9Hz,3H),3.19(s,3H),2.72(t,J=4.7Hz,2H),2.53-2.56(m,4H),2.21(t,J=5.9Hz, 2H),1.83-1.88(m,2H),1.68-1.73(m,7H),0.98(t,J=7.1Hz,3H); MS(ESI)m / z:520.4(M+H + ).
[0501] R 4 General method for partial acylation:
[0502] Example 36: 1-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-cyclopropylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one
[0503]
[0504] A solution of 1-(3-((2-((2-cyclopropyl-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one (34, 0.21 g, 0.40 mmol) in 2.5 mL 30% MeCN:water was treated with acetic anhydride (1.0 equiv) at rt. The reaction mixture was stirred at rt for 30 min and the solution was diluted with water (15 mL). The solution was extracted with EtOAc (3 x 20 mL) and the combined organics were washed with saturated NaHCO (15 mL). The organic layer was dried over MgSO, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0% to 10% DCM / MeOH, 25CV) to give 1-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-cyclopropylphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)piperidin-2-one (0.13 g, 57% yield) as a clear glassy solid. 1H NMR (400MHz, DMSO-d6): δ8.64(brs,1H),8.04(s,1H),7.27(s,1H),7.05(brs,1H),6.75(d,1H),6.46(s,1H),3.54(d,4H),3.01-3.24 (m,10H),2.18-2.19(m,2H),2.02(s,3H),1.91-1.96(m,1H),1.61-1.67(m,6H),0.82(d,2H),0.58(d,2H); LC-MS(ESI)m / z:560.4(M+H) + .
[0505] General Method M: Pd Coupling Reaction
[0506] Example 97: 1-(3-((2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one
[0507]
[0508] A mixture of commercially available 5-(4-methylpiperazin-1-yl)pyridin-2-amine (0.13 g, 0.66 mmol) and 1-(3-((2-chloro-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one (M-1, 0.20 g, 0.60 mmol) in 1,4-dioxane (3 mL) was treated with cesium carbonate (0.39 g, 1.2 mmol). The solution was sparged with Ar and treated with Pd2(dba)3 (0.055 g, 0.06 mmol) and Xantphos (0.069 g, 0.12 mmol). The mixture was sparged with Ar again, the lid was tightly sealed and heated at 90 °C for 15 h. The mixture was cooled to rt, diluted with DCM (20 mL) and water (10 mL). The black solid was filtered off and the filtrate was then treated with brine. The solution was extracted with additional DCM (3 x 25 mL). The combined organics were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(3-((2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)propyl)piperidin-2-one (0.18 g, 57% yield) as an orange solid. 1H NMR (400MHz, DMSO-d6): δ9.35(s,1H),8.01(s,1H),7.90(d,J=3.0Hz,1H),7.55( d,J=9.1Hz,1H),7.37(dd,J=9.1 and 3.1Hz,1H),7.11(s,1H),6.19-6.21(m,1H),3.3 1-3.35(m,2H),3.22-3.26(m,2H),3.13(q,J=6.5Hz,2H),3.05-3.10(m,4H),2.4 4-2.49(m,4H),2.20-2.23(m,5H),1.66-1.76(m,6H); LC-MS(ESI)m / z:492.2(M+H + ).
[0509] Table I. Exemplary compounds.
[0510]
[0511]
[0512]
[0513]
[0514]
[0515]
[0516]
[0517]
[0518]
[0519]
[0520]
[0521]
[0522]
[0523]
[0524]
[0525]
[0526]
[0527]
[0528]
[0529]
[0530]
[0531]
[0532]
[0533]
[0534]
[0535]
[0536]
[0537] Example 130. ULK1.2 (SEQ. ID NO: 1) biochemical assay
[0538] The activity of ULK1 kinase was determined spectroscopically using a coupled pyruvate kinase / lactate dehydrogenase assay that continuously monitors ATP hydrolysis-dependent NADH oxidation (e.g., Schindler et al. Science (2000) 289: 1938-1942). The assay was performed in a 384-well plate (100 μL final volume) using an assay buffer (100 mM Tris pH 7.5, 15 mM MgCl2, 0.5 mM DTT, 0.1% octyl glucoside, 0.002% (w / v) BSA, and 0.002% Triton X-100) containing 19 nM ULK1 (Eurofins catalog number 14-959), 0.25 mg / mL myelin basic protein, 1.5 units pyruvate kinase, 2.1 units lactate dehydrogenase, 1 mM pyruvate phosphoenolase, 0.28 mM NADH, and 1 mM ATP). ULK1 inhibition was measured by adding serially diluted test compounds (final assay concentration was 1% DMSO). The decrease in absorbance at 340 nm was continuously monitored for 6 hours at 30° C. on a multimode microplate reader (BioTek). Reaction rates were calculated using a 2-3 hour period. The reaction rates at each concentration of compound were converted to percent inhibition using controls (i.e., reactions without test compounds and reactions with known inhibitors), and the IC was calculated by fitting a four-parameter sigmoidal curve to the data using Prism (GraphPad software). 50 value.
[0539] ULK1 protein sequence (residues 1-314 with N-terminal His tag; SEQ. ID NO: 1)
[0540] MSYYHHHHHHDYDIPTTENLYFQGAMDPFFMEPGRGGTETVGKFEFSRKDLIGHGAFAVVFKGRHREKHDLEVAVKCINKKNLAKSQTLLGKEIKILKELKHENIVALYDFQEMANSVYLVMEYCNGGDLADYLHAMRTLLSEDTIRLFLQQIAGAMRLLHSKGIIHRDLKPQ NILLSNPAGRRANPNSIRVKIADFGFARYLQSNMMAATLCGSPMYMAPEVIMSQHYDGKADLWSIGTIVYQCLTGKAPFQASSPQDLRLFYEKNKTLVPTIPRETSAPLRQLLLALLQRNHKDRMDFDEFFHHPFLDASPSVRKSPPVPVPSYPSSGSGSSSSSSSTSHLAS
[0541] Example 131. ULK1.3 (SEQ. ID NO: 2) biochemical assay
[0542] The activity of ULK1 kinase was determined spectroscopically using a coupled pyruvate kinase / lactate dehydrogenase assay that continuously monitors ATP hydrolysis-dependent NADH oxidation (e.g., Schindler et al. Science (2000) 289: 1938-1942). The assay was performed in a 384-well plate (100 μL final volume) using 0.1 nM ULK1 (from Beryllium), 0.075 mM peptide substrate (YANWLAASIYLDGKKK), 1.5 units of pyruvate kinase, 2.1 units of lactate dehydrogenase, 1 mM pyruvate phosphoenolase, 0.28 mM NADH, and 1 mM ATP in assay buffer (100 mM Tris pH 7.5, 15 mM MgCl2, 0.5 mM DTT, 0.004% (w / v) BSA, and 0.004% Triton X-100). ULK1 inhibition was measured by adding serially diluted test compounds (final assay concentration was 1% DMSO). The decrease in absorbance at 340 nm was continuously monitored for 6 hours at 30° C. on a multimode microplate reader (BioTek). Reaction rates were calculated using a 2-3 hour period. The reaction rates at each concentration of compound were converted to percent inhibition using controls (i.e., reactions without test compounds and reactions with known inhibitors), and the IC was calculated using software routines in Prism (GraphPad software).50 value.
[0543] ULK1 protein sequence (residues 1-283; SEQ. ID NO: 2)
[0544] MEPGRGTETVGKFEFSRKDLIGHGAFAVVFKGRHRAAHDLEVAVKCINKKNLAKSQTLLGKEIKILKELKHENIVALYDFQEMANSVYLVMEYCNGGDLADYLHAMRTLSEDTIRLFLQQIAGAMRLLHSKGIIHRDLKP QNILLSNPAGRRANPNSIRVKIADFGFARYLQSNMMAATLCGSPMYMAPEVIMSQHYDGKADLWSIGTIVYQCLTGKAPFQASSPQDLRLFYEKNKTLVPTIPRETSAPLRQLLLALLQRNHKDRMDFDEFFHHPFLDASPS
[0545] Example 132. ULK2 (SEQ. ID NO: 3) biochemical assay
[0546] The activity of ULK2 kinase was determined spectroscopically using a coupled pyruvate kinase / lactate dehydrogenase assay that continuously monitors ATP hydrolysis-dependent NADH oxidation (e.g., Schindler et al. Science (2000) 289: 1938-1942). The assay was performed in a 384-well plate (100 μL final volume) using an assay buffer (100 mM Tris pH 7.5, 15 mM MgCl2, 0.5 mM DTT, 0.1% octyl glucoside, 0.002% (w / v) BSA, and 0.002% Triton X-100) containing 9.7 nM ULK2 (Eurofins catalog number 14-772), 0.25 mg / mL myelin basic protein, 1.5 units pyruvate kinase, 2.1 units lactate dehydrogenase, 1 mM pyruvate phosphoenolase, 0.28 mM NADH, and 1 mM ATP). ULK2 inhibition was measured by adding serially diluted test compounds (final assay concentration was 1% DMSO). The decrease in absorbance at 340 nm was continuously monitored for 6 hours at 30° C. on a multimode microplate reader (BioTek). Reaction rates were calculated using a 2-3 hour period. The reaction rates at each concentration of compound were converted to percent inhibition using controls (i.e., reactions without test compounds and reactions with known inhibitors), and the IC was calculated by fitting a four-parameter sigmoidal curve to the data using Prism (GraphPad software). 50 value.
[0547] ULK2 protein sequence (residues 1-306 with N-terminal GST and His tag; SEQ. ID NO: 3)
[0548] MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKD FETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGPE FMEVVGDFEYSKRDLVGHGAFAVVFRGRHRQKTDWEVAIKSINKKNLSKSQILLGKEIKILKELQHENIVALYDVQELPNSVFLVMEYCNGGDLADYLQAKGTLSEDTIRVFLHQ IAAAMRILHSKGIIHRDLKPQNILLSYANRRKSSVSGIRIKIADFGFARYLHSNMMAATLCGSPMYMAPEVIMSQHYDAKADLWSIGTVIYQCLVGKPPFQANSPQDLRMFYEKN RSLMPSIPRETSPYLANLLLGLLQRNQKDRMDFEAFFSHPFLEQGPVKKSCPVPVPMYSGSVSGSSCGSSPSCRFASHHHHHH
[0549] Table 1. Inhibition of biochemical activity of ULK1 and ULK2 kinases by the exemplary compounds shown in Table 1.
[0550]
[0551]
[0552]
[0553] For Table 1, "+" means IC greater than 1 nM and less than or equal to 25 nM 50 ; "++" means IC greater than 25nM and less than or equal to 100nM 50 ; "+++" means IC greater than 100nM and less than or equal to 500nM 50 ; and "++++" means an IC greater than 500nM 50 .
[0554] Example 133. Cellular Inhibition of ULK Kinase Substrate ATG13 Protein
[0555] pATG13 content of mutant KRas A549 cells after treatment with ULK inhibitor and trametinib.
[0556] A549 (KRAS mutation) human lung cancer cells (6,000 cells / well) were added to 50 μL pre-warmed DMEM medium supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA), 100 units / mL penicillin G, and 100 μg / mL streptomycin in a 384-well tissue culture treated plate and grown overnight at 37°C, 5% CO2, and 95% humidity. The next day, 10 μL of culture medium containing trametinib or DMSO as a control was added to the wells. The final concentration of trametinib in the wells was 250 nM. Dose responses of test compounds (0.6 μL / well) were added. DMSO (0.6 μL) was added to the control wells. The plate was shaken briefly to mix the wells, and then incubated overnight at 37°C. The next day, the culture medium was aspirated and the cells were washed with Dulbecco's phosphate buffered saline (Gibco). Cells were lysed with MPER lysis buffer (Pierce, Rockford, IL) containing Halt phosphatase and protease inhibitors (Pierce, Rockford, IL) and phosphatase inhibitor cocktail 2 (Sigma, St. Louis, MO) at 4°C for 10 min with shaking.
[0557] Cellular levels of phosphoserine 318ATG13 (pATG13) were measured via ELISA. A full ATG13 antibody (Cell Signaling catalog number 13273) was used to coat the wells. The plate was incubated overnight at 4°C and washed with ELISA wash buffer (Biolegend catalog number 421601). Subsequently, the wells were blocked with assay diluent (Biolegend catalog number 421203) for 1 hour at room temperature. The wells were washed with ELISA wash buffer. Cell lysates were added to the wells and incubated at room temperature for 2 hours. The wells were washed with ELISA wash buffer. Biotin-labeled pS318-ATG13 antibody (Rockland Immunochemicals catalog number 600-401-C49) was diluted in assay diluent and added to each well and incubated at room temperature for 1 hour. The wells were washed with ELISA wash buffer. The streptavidin (ThermoFisher catalog number 21140) linked to horseradish peroxidase was diluted in assay diluent and added to each well and incubated at room temperature for 1 hour. The plate wells were washed with ELISA wash buffer. Highly sensitive TMB substrate (Biolegend catalog number 421101) was added to each well and incubated at room temperature for 20 minutes. The reaction was terminated with 2N sulfuric acid. The plate was analyzed on a plate reader measuring the absorbance at 450nm and 540nm (background). For each well, the signal was calculated by first subtracting the background absorbance at 540nm from the absorbance at 450nm. Next, the background corrected absorbance at 450nm of the blank group wells was subtracted from the test wells. The data were compared with the control wells to determine ATG13 phosphorylation%. GraphPad Prism was used to calculate IC 50 value.
[0558] Example 134. pATG13 content of mutant KRas MiaPaCa-2 cells after treatment with ULK inhibitor and trametinib.
[0559] MiaPaCa-2 human pancreatic cancer cells (10,000 cells / well) were added to 50 μL pre-warmed DMEM medium supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA), 100 units / mL penicillin G, 100 μg / mL streptomycin, and 2.5% horse serum in a 384-well tissue culture treated dish and grown overnight at 37°C, 5% CO2, and 95% humidity. The next day, 10 μL of culture medium containing trametinib or DMSO as a control was added to the well. The final concentration of trametinib in the well was 250 nM. A dose response of the test compound (0.6 μL / well) was added. DMSO (0.6 μL) was added to the control well. The dish was shaken briefly to mix the wells, and then incubated overnight at 37°C. The next day, the culture medium was aspirated and the cells were washed with Dulbecco's phosphate buffered saline (Gibco). Cells were lysed with MPER lysis buffer (Pierce, Rockford, IL) containing Halt phosphatase and protease inhibitors (Pierce, Rockford, IL) and phosphatase inhibitor cocktail 2 (Sigma, St. Louis, MO) at 4°C for 10 min with shaking.
[0560] The cellular content of phosphoserine 318ATG13 (pATG13) was measured via ELISA. A full ATG13 antibody (Cell Signaling catalog number 13273) was used to coat the wells. The plate was incubated overnight at 4°C and washed with ELISA wash buffer (Biolegend catalog number 421601). Subsequently, the wells were blocked with assay diluent (Biolegend catalog number 421203) for 1 hour at room temperature. The wells of the plate were washed with ELISA wash buffer. Cell lysates were added to the wells and incubated at room temperature for 2 hours. The wells of the plate were washed with ELISA wash buffer. The pS318-ATG13 antibody (Rockland Immunochemicals catalog number 600-401-C49) labeled with biotin was diluted in assay diluent and added to each well and incubated at room temperature for 1 hour. The wells of the plate were washed with ELISA wash buffer. The streptavidin (ThermoFisher catalog number 21140) linked to horseradish peroxidase was diluted in assay diluent and added to each well and incubated at room temperature for 1 hour. The plate wells were washed with ELISA wash buffer. Highly sensitive TMB substrate (Biolegend catalog number 421101) was added to each well and incubated at room temperature for 20 minutes. The reaction was terminated with 2N sulfuric acid. The plate was analyzed on a plate reader measuring the absorbance at 450nm and 540nm (background). For each well, the signal was calculated by first subtracting the background absorbance at 540nm from the absorbance at 450nm. Next, the background corrected absorbance at 450nm of the blank group wells was subtracted from the test wells. The data were compared with the control wells to determine ATG13 phosphorylation%. GraphPad Prism was used to calculate IC 50 value.
[0561] Example 135. pATG13 content of mutant KRas HCT-116 cells after treatment with ULK inhibitor and trametinib.
[0562] HCT-116 human colon cancer cells (10,000 cells / well) were added to 50 μL pre-warmed DMEM medium supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA), 100 units / mL penicillin G, and 100 μg / mL streptomycin in a 384-well tissue culture treated dish and grown overnight at 37°C, 5% CO2, and 95% humidity. The next day, 10 μL of culture medium containing trametinib or DMSO as a control was added to the well. The final concentration of trametinib in the well was 250 nM. A dose response of the test compound (0.6 μL / well) was added. DMSO (0.6 μL) was added to the control well. The dish was shaken briefly to mix the wells, and then incubated overnight at 37°C. The next day, the culture medium was aspirated and the cells were washed with Dulbecco's phosphate buffered saline (Gibco). Cells were lysed with MPER lysis buffer (Pierce, Rockford, IL) containing Halt phosphatase and protease inhibitors (Pierce, Rockford, IL) and phosphatase inhibitor cocktail 2 (Sigma, St. Louis, MO) at 4°C for 10 min with shaking.
[0563] The cellular content of phosphoserine 318ATG13 (pATG13) was measured via the ELISA method. A full ATG13 antibody (Cell Signaling catalog number 13273) was used to coat the wells. The plate was incubated overnight at 4°C and washed with ELISA wash buffer (Biolegend catalog number 421601). Subsequently, the wells were blocked with assay diluent (Biolegend catalog number 421203) for 1 hour at room temperature. The wells of the plate were washed with ELISA wash buffer. Cell lysates were added to the wells and incubated for 2 hours at room temperature. The wells of the plate were washed with ELISA wash buffer. The pS318-ATG13 antibody (Rockland Immunochemicals catalog number 600-401-C49) labeled with biotin was diluted in assay diluent and added to each well and incubated for 1 hour at room temperature. The wells of the plate were washed with ELISA wash buffer. The streptavidin (ThermoFisher catalog number 21140) linked to horseradish peroxidase was diluted in assay diluent and added to each well and incubated at room temperature for 1 hour. The plate wells were washed with ELISA wash buffer. Highly sensitive TMB substrate (Biolegend catalog number 421101) was added to each well and incubated at room temperature for 20 minutes. The reaction was terminated with 2N sulfuric acid. The plate was analyzed on a plate reader measuring the absorbance at 450nm and 540nm (background). For each well, the signal was calculated by first subtracting the background absorbance at 540nm from the absorbance at 450nm. Next, the background corrected absorbance at 450nm of the blank group wells was subtracted from the test wells. The data were compared with the control wells to determine ATG13 phosphorylation%. GraphPad Prism was used to calculate IC 50 value.
[0564] Example 136. pATG13 content of mutant BRAF A375 cells after treatment with ULK inhibitor and trametinib.
[0565] A375 human malignant melanoma cancer cells (20,000 cells / well) were added to 100 μL pre-warmed DMEM medium supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA), 100 units / mL penicillin G, and 100 μg / mL streptomycin in a 96-well tissue culture treated dish and grown overnight at 37°C, 5% CO2, and 95% humidity. The next day, 100 μL of culture medium containing trametinib or DMSO as a control was added to the wells. The final concentration of trametinib in the wells was 250 nM. Dose responses of test compounds (0.5 μL / well) were added. DMSO (0.5 μL) was added to the control wells. The dish was shaken briefly to mix the wells, and then incubated overnight at 37°C. The next day, the culture medium was aspirated and the cells were washed with Dulbecco's phosphate buffered saline (Gibco). Cells were lysed with MPER lysis buffer (Pierce, Rockford, IL) containing Halt phosphatase and protease inhibitors (Pierce, Rockford, IL) and phosphatase inhibitor cocktail 2 (Sigma, St. Louis, MO) at 4°C for 10 min with shaking.
[0566] The cellular content of phosphoserine 318ATG13 (pATG13) was measured via the ELISA method. A full ATG13 antibody (Cell Signaling catalog number 13273) was used to coat the wells. The plate was incubated overnight at 4°C and washed with ELISA wash buffer (Biolegend catalog number 421601). Subsequently, the wells were blocked with assay diluent (Biolegend catalog number 421203) for 1 hour at room temperature. The wells of the plate were washed with ELISA wash buffer. Cell lysates were added to the wells and incubated for 2 hours at room temperature. The wells of the plate were washed with ELISA wash buffer. The pS318-ATG13 antibody (Rockland Immunochemicals catalog number 600-401-C49) labeled with biotin was diluted in assay diluent and added to each well and incubated for 1 hour at room temperature. The wells of the plate were washed with ELISA wash buffer. The streptavidin (ThermoFisher catalog number 21140) linked to horseradish peroxidase was diluted in assay diluent and added to each well and incubated at room temperature for 1 hour. The plate wells were washed with ELISA wash buffer. Highly sensitive TMB substrate (Biolegend catalog number 421101) was added to each well and incubated at room temperature for 20 minutes. The reaction was terminated with 2N sulfuric acid. The plate was analyzed on a plate reader measuring the absorbance at 450nm and 540nm (background). For each well, the signal was calculated by first subtracting the background absorbance at 540nm from the absorbance at 450nm. Next, the background corrected absorbance at 450nm of the blank group wells was subtracted from the test wells. The data were compared with the control wells to determine ATG13 phosphorylation%. GraphPad Prism was used to calculate IC 50 value.
[0567] Example 137. pATG13 content of mutant HRas T24 cells after treatment with ULK inhibitor and trametinib.
[0568] T24 human bladder cancer cells (25000 cells / well) were added to 100 μL pre-warmed DMEM medium supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA), 100 units / mL penicillin G, and 100 μg / mL streptomycin in a 96-well tissue culture treated dish and grown overnight at 37°C, 5% CO2, and 95% humidity. The next day, 100 μL of culture medium containing trametinib or DMSO as a control was added to the wells. The final concentration of trametinib in the wells was 250 nM. Dose responses of test compounds (0.5 μL / well) were added. DMSO (0.5 μL) was added to the control wells. The dish was shaken briefly to mix the wells, and then incubated overnight at 37°C. The next day, the culture medium was aspirated and the cells were washed with Dulbecco's phosphate buffered saline (Gibco). Cells were lysed with MPER lysis buffer (Pierce, Rockford, IL) containing Halt phosphatase and protease inhibitors (Pierce, Rockford, IL) and phosphatase inhibitor cocktail 2 (Sigma, St. Louis, MO) at 4°C for 10 min with shaking.
[0569] The cellular content of phosphoserine 318ATG13 (pATG13) was measured via the ELISA method. A full ATG13 antibody (Cell Signaling catalog number 13273) was used to coat the wells. The plate was incubated overnight at 4°C and washed with ELISA wash buffer (Biolegend catalog number 421601). Subsequently, the wells were blocked with assay diluent (Biolegend catalog number 421203) for 1 hour at room temperature. The wells of the plate were washed with ELISA wash buffer. Cell lysates were added to the wells and incubated for 2 hours at room temperature. The wells of the plate were washed with ELISA wash buffer. The pS318-ATG13 antibody (Rockland Immunochemicals catalog number 600-401-C49) labeled with biotin was diluted in assay diluent and added to each well and incubated for 1 hour at room temperature. The wells of the plate were washed with ELISA wash buffer. The streptavidin (ThermoFisher catalog number 21140) linked to horseradish peroxidase was diluted in assay diluent and added to each well and incubated at room temperature for 1 hour. The plate wells were washed with ELISA wash buffer. Highly sensitive TMB substrate (Biolegend catalog number 421101) was added to each well and incubated at room temperature for 20 minutes. The reaction was terminated with 2N sulfuric acid. The plate was analyzed on a plate reader measuring the absorbance at 450nm and 540nm (background). For each well, the signal was calculated by first subtracting the background absorbance at 540nm from the absorbance at 450nm. Next, the background corrected absorbance at 450nm of the blank group wells was subtracted from the test wells. The data were compared with the control wells to determine ATG13 phosphorylation%. GraphPad Prism was used to calculate IC 50 value.
[0570] Table 2. ULK kinase inhibition in mutant Ras or mutant BRAF cell lines by exemplary compounds shown in Table I.
[0571]
[0572]
[0573]
[0574] For Table 2, “+” means IC greater than 10 nM and less than or equal to 100 nM 50 ; "++" means IC greater than 100nM and less than or equal to 300nM 50 ; "+++" means IC greater than 300nM and less than or equal to 600nM 50 ; and "++++" means an IC greater than 600nM 50 .
[0575] Example 138. LRRK2 (SEQ. ID NO: 4) biochemical assay
[0576] The activity of LRRK2 kinase was determined spectroscopically using a coupled pyruvate kinase / lactate dehydrogenase assay that continuously monitors ATP hydrolysis-dependent NADH oxidation (e.g., Schindler et al. Science (2000) 289: 1938-1942). The assay was performed in a 384-well plate (100 μL final volume) using an assay buffer (100 mM Tris pH 7.5, 15 mM MgCl2, 0.5 mM DTT, 0.004% (w / v) BSA, and 0.004% Triton X-100) containing 26.4 nM LRRK2 (Thermo Fisher), 0.1 mM peptide substrate (RLGRDKYKTLRQIRQ), 1.5 units of pyruvate kinase, 2.1 units of lactate dehydrogenase, 1 mM pyruvate phosphoenolase, 0.28 mM NADH, and 1 mM ATP). LRRK2 inhibition was measured by adding serially diluted test compounds (final assay concentration was 1% DMSO). The decrease in absorbance at 340 nm was continuously monitored for 6 hours at 30° C. on a multimode microplate reader (BioTek). Reaction rates were calculated using a 2-3 hour period. The reaction rates at each concentration of compound were converted to percent inhibition using controls (i.e., reactions without test compounds and reactions with known inhibitors), and the IC was calculated using software routines in Prism (GraphPad software). 50 value.
[0577] LRRK2 protein sequence (residues 970-2528; SEQ. ID NO: 4)
[0578] MAPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRHNQTSLYKKAGTMHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMK LMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACM
[0579] SKITKELLNKRGFPAIRDYHFVNATEESDALAKL
[0580] RKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELP
[0581] HAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSK
[0582] KRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWS
[0583] RLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKG
[0584] CILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLL
[0585] VNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFN
[0586] KHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIAL
[0587] HVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEV
[0588] ARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEK
[0589] LIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDR
[0590] GQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTD
[0591] SVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNST
[0592] ERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDK
[0593] KTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRL
[0594] IRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEK
[0595] HIEVRKELAEKMRRTSVE
[0596] Table 3. LRRK2 kinase inhibition by exemplary compounds shown in Table 1.
[0597]
[0598]
[0599] For Table 3, "+" means IC greater than 1 nM and less than or equal to 100 nM 50 ; "++" means IC greater than 100nM and less than or equal to 300nM 50 ; "+++" means IC greater than 300nM and less than or equal to 600nM 50 ; and "++++" means an IC greater than 600nM 50 .
[0600] Example 139. Evaluation of ULK inhibitors in pancreatic ductal adenocarcinoma (PDAC) in vitro and in vivo
[0601] ULK inhibitors were evaluated in a PDAC flux assay, and a panel of inhibitors including those derived from Trp53 lox / + 、LSL-Kras G12D 、Rosa-rtTA LSL 、p48Cre + IC of compounds in multiple PDAC cell lines with primary tumor cells 50 This should be measured using colony generation 2D assays and 3D organoid assays in the absence or presence of trametinib.
[0602] To evaluate inhibition of autophagic flux using a flux reporter in PDAC tumors in vivo following single and multiple doses using a syngeneic orthotopic model.
[0603] The therapeutic efficacy of ULK inhibitors in PDAC models should be evaluated by: (i) evaluating PDAC tumor kinetics subcutaneously; (ii) evaluating PDAC tumor kinetics orthotopically in the pancreas (C57 black mice implanted with KPCs) in a syngeneic model; (iii) evaluating tumor growth kinetics in a syngeneic model using a ULK inhibitor and a MEK inhibitor; (iv) evaluating compounds in a syngeneic model of PDAC; (v) evaluating histological changes in the tumor microenvironment; (vi) evaluating changes in immune cell infiltration in tumors after ULK inhibitor inhibition; and (vii) evaluating the efficacy of ULK inhibitors and immune checkpoint blockade.
[0604] Equivalent solutions
[0605] Although specific embodiments have been discussed, the above description is illustrative and non-limiting. Many variations of the embodiments will be apparent to those skilled in the art upon reviewing this specification. The full scope of the disclosure and its equivalents and the full scope of this specification and such variations should be determined by reference to the claims.
[0606] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood in all instances as modified by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained.
Claims
1. A compound represented by: or a pharmaceutically acceptable salt, enantiomer, stereoisomer or tautomer thereof, wherein: W is CH or N; X is CH or N; Y is C(R 3 ) or N; R 1 is selected from the group consisting of halogen, cyano, C1-C5 alkyl and C3-C5 cycloalkyl, wherein each C1-C5 alkyl and C3-C5 cycloalkyl may be optionally substituted with one, two or three independent occurrences of fluorine; R 2 Selected from the group consisting of H, halogen, cyano, C1-C5 alkyl, C3-C6 cycloalkyl, C2-C5 alkenyl, C2-C5 alkynyl, C1-C5 alkoxy and C1-C5 alkoxy-C2-C5 alkyl, wherein each C1-C5 alkyl, C3-C6 cycloalkyl, C2-C5 alkenyl, C2-C5 alkynyl and C1-C5 alkoxy may be optionally substituted by one, two or three independent occurrences of fluorine or cyano; R 3 and R 33 is independently selected at each occurrence from the group consisting of: H, halogen, C 1- C6 alkyl and C 1- C6 alkoxy, wherein each C1-C6 alkyl and C1-C6 alkoxy may be optionally substituted with one or more independent occurrences of fluorine; R 4 Selected from the following group: B, D, NR 6 R 9 NR 6 -(C(R 10 )2) p -NR 9 R 9 、C(O)-NR 6 R 9 ; C(O)-B; C(O)-D and CN; B is selected from N-linked heterocyclic groups and heteroaryls having at least one nitrogen and optionally additional ring nitrogen or oxygen, wherein B may be optionally substituted on one or more available carbons by R 7 substituted and optionally substituted on an available nitrogen by R 9 replace; D is selected from C-linked heterocyclic and heteroaryl groups having at least one nitrogen and optionally additional ring nitrogen or oxygen, wherein D may be optionally substituted on one or more available carbons by R 7 substituted and optionally substituted on an available nitrogen by R 9 replace; R 5 is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and heterocyclyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; R 7 is independently selected at each occurrence from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, cyano, and (C(R 10 )2) h -NR 9 R 9 , wherein each C1-C6 alkyl group and C3-C6 cycloalkyl group may be optionally substituted by one or more independently occurring fluorine groups, or two R 7 Joined with the atom to which it is attached to form an oxo group; R 6 and R 9 Each occurrence is independently selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, C 1- C5 alkoxy-C2-C5 alkyl, C(=O)R 5 、SO2R 5 and D, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine; R 10 R is independently selected at each occurrence from the group consisting of H, C1-C3 alkyl and C3-C5 cycloalkyl, wherein each C1-C3 alkyl and C3-C5 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 10 Joined together with the carbon to which it is attached to form a C3-C5 cycloalkyl group; Z is selected from the following group: a 4-membered lactam ring bonded via a nitrogen atom or a 6-10-membered lactam ring bonded via a nitrogen atom, wherein when the lactam ring is a 6-10-membered ring, the lactam ring atom may optionally be oxygen or NR 6 , and the available carbon atoms on the 4-membered lactam ring or the 6-10-membered lactam are optionally replaced by R 36 replace; R 36 R is independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, wherein each C1-C6 alkyl and C3-C6 cycloalkyl may be optionally substituted with one or more independent occurrences of fluorine, or two R 36 Joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl group; h is 1, 2, or 3; m is 0, 1, 2 or 3; n is 2, 3 or 4; and p is 2 or 3; The condition is that X and Y are not both N.
2. The compound of claim 1, wherein W is N.
3. A compound as claimed in claim 1 or claim 2, wherein X is CH and Y is N.
4. A compound as claimed in claim 1 or claim 2, wherein X is CH and Y is C(R 3 ).
5. The compound according to any one of claims 1 to 4, wherein Z is selected from: and in, V is selected from the group consisting of oxygen, C(R 34 )2 and NR 6 ; R 34 independently selected at each occurrence from H and R 36 , where R 36 are independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, or two R 36 Joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl group; q is 0, 1, 2, or 3; and r is 2 or 4; The condition is that if q is 0, then r is not 2.
6. The compound according to any one of claims 1 to 5, wherein Z is selected from: and in, V is selected from the group consisting of oxygen, C(R 34 )2 and NR 6 ; R 34 independently selected at each occurrence from H and R 36 , where R 36 are independently selected at each occurrence from C1-C6 alkyl and C3-C6 cycloalkyl, or two R 36 Joined together with the carbon to which it is attached to form a C3-C6 cycloalkyl group; q is 0, 1, 2, or 3; and r is 2 or 3; The condition is that if q is 0, then r is not 2.
7. A compound according to any one of claims 1 to 6, wherein Z is selected from the following group: and 8. A compound according to any one of claims 1 to 7, wherein Z is selected from: and in, V is selected from the group consisting of oxygen, C(R 34 )2 and NR 6 ; q is 0, 1, 2, or 3; and r is 2 or 3; The condition is that if q is 0, then r is not 2.
9. The compound according to any one of claims 1 to 8, wherein Z is selected from the following group: and 10. The compound according to any one of claims 1 to 9, wherein R 4 For B.
